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iAbstract
Surgical treatment, radiation therapy, and chemotherapy drugs are used to treat cancer. However, 
this treatment often kills normal cells and causes side effects. In addition, most cancer drugs are 
hydrophobic and therefore pose a number of problems to apply to the body. To solve this problem, 
nanomedicinehas been used for cancer treatment. This nanomedicine selectively accumulates to the 
cancer cells through passive and active targeting.
Organic nanomedicine, involving micelle, liposomes, and proteins, has low stability in the body. 
Inorganic nanomedicine, on the other hand, has high stability, but a low loading capacity because it is 
limited to the direct modification method. To overcome this challenge, research has been conducted 
into porous materials in drug delivery. Porous material has high body-stability and drug-loading 
capacity. In addition, a variety of functional molecules are modified to the outer and inner surfaces, 
and the multifunctionality of porous materials facilitates stimulated drug release. 
In this dissertation, various stimuli-responsive porous materials were described for cancer therapy. 
A membrane composed of a Dendrimer (Den) and a gold nanorod (GNR) has pores through which 
the drug can be released. In addition, GNR shows the effect of surface plasmon resonance (SPR) even 
after membrane synthesis, and it generates heat by NIR irradiation and increases the local temperature 
that promotes drug release. This controlled release of the drug sustains the drug concentration within 
the therapeutic window, thereby reducing side effects and enhancing benefits.
Unlike bare GNR, GNR capped with mesoporous silica (GNR@MS) has pores that facilitate drug 
loading, thereby increasing the chemotherapy effect of nanoparticles. However, the weak interaction 
between the drug and the MS surface causes the loaded drug to be released from the nanoparticle 
during the delivery process. In order to prevent premature release, a glutathione (GSH)-responsive 
polymer (PEG-PDS) is coated on GNR@MS surfaces to block the pores. Polymer coated GNR@MS 
(GNR@MS@PDS) increases the local temperature in response to NIR irradiation, which induces 
drug-release by expanding PEG-PDS. Furthermore, the PEG-PDS polymer is degraded by GSH, 
opening the pore of GN @MS and releasing the drug at the cancer cells. This dual-stimulus system 
can control the time and space of drug release in the body.
NanoMOF with high surface and porosity is attracting much attention as a drug-delivery system. In 
particular, PCN-224 has high stability in aqua state, and the porphyrin derivative organic linker 
constituting of PCN is used as a PDT agent. That facilitates the photodynamic therapy under light 
irradiation without any additional processes. These properties enable combined chemo & PDT to 
enhance cancer treatment effectiveness. In addition, MOF can be easily modified by hyaluronic acid, 
while HA can control the drug release in response to HAdase as well as interact with the CD44 
ii
receptor to selectively target cancer.
The unsaturated metal clusters of nanoMOF can form a coordination bond with the Lewis base, and 
the nanoMOF can easily be post-functionalized using this character. Various systems use this 
phenomenon to convert the cancer-targeting ligand to MOF. However, proteins and biochemicals, 
which have Lewis bases, are present in the body and compete with modified ligands to interact with 
MOF and induce ligand detachment. To overcome these problems, Folic acid-modified polyacrylic 
acid (PAA) was coated to the MOF surface. The polyvalent coordination between PAA and MOF 
increases the binding force of the ligand and the stability of the drug-delivery system in the body.
Stimulus-responsive systems based on porous materials can effectively treat cancer with advantages 
like drug-concentration control, dual-stimulus response, combined therapy and increased biostability.
iii
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Figure 1-1. Timeline with some examples of nanoparticles approved by Food and Drug 
Administration.) Doxil® is the liposomal doxorubicin formulation; Feridex® includes 
superparamagnetic iron nanoparticles associated with dextran, DaunoXome® is the liposomal 
daunorubicin, Mylotarg® has gemtuzumab ozogamicin molecules bonded to monoclonal antibody, 
Zevalin® includes mouse monoclonal antibody IgG1 with tiuxetan chelator associated with 
radioactive isotope Yttrium-90, Abraxane® has paclitaxel bonded to albumin; Oncaspar® is the 
modified version of the L-asparaginase enzyme, and Ontak® includes the fusion protein denileukin 
diftitox. Reproduced with permission.16 Copyright 2016, Scientific Electronic Library Online.
Figure 1-2. Schematic representation of different mechanisms by which nanomedicine can deliver 
drugs to tumors. Nanomedicine are shown as representative nanocarriers (circles). Passive tissue 
targeting is achieved by extravasation of nanomedicine through increased permeability of the tumor 
vasculature and ineffective lymphatic drainage (EPR effect). Active cellular targeting (inset) can be 
achieved by functionalizing the surface of nanomedicine with ligands that promote cell-specific 
recognition and binding. The nanomedicine can (i) release their contents in close proximity to the 
target cells; (ii) attach to the membrane of the cell and act as an extracellular sustained-release drug 
depot; or (iii) internalize into the cell. Reproduced with permission.23 Copyright 2007, Nature 
Publishing Group.
Figure 1-3. Schematic illustration of the formation of Den-NP porous meterial films and the 
incorporation and release of dyes or drugs and b) an AFM image of Den-GNP porous films on an 
amine-functionalized glass surface. The bottom graph shows the line profile image and a film 
thickness of ≈ 700 nm determined by profilometry. Reproduced with permission.36 Copyright 2011, 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figure 1-4. Schematic illustration of fabrication and post-functionalization of hybrid porous material 
membranes. (a) A glass filter, hybrid membrane consisting of Den-GNP composites formed. (b) 
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functionalities. Reproduced with permission.35 Copyright 2012, WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim.
Figure 1-5. a: Synthesis of gold nanorods from spherical gold seeds in the presence of CTAB as a 
shape-directing agent in water at room temperature, showing a cartoon of the final CTAB bilayer. b: 
UV–Vis spectra, transmission electron micrographs, and photographs of aqueous solutions of gold 
nanorods of different aspect ratio (length/width). Aspect ratio increases from left to right. All scale 
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bars=100 nm. The yellow shaded area of the spectra is the biological “water window”. Reproduced 
with permission.38 Copyright 2011, Elsevier B.V..
Figure 1-6. A) Schematic illustration of GNR@MS as a novel multifunctional theranostic platform 
for cancer treatment. TEM images of B) GNR and C) GNR@MS, D) extinction spectra of GNR, 
GNR@MS, and Dox-GNR@MS, and E) DOX release profiles from Dox-GNR@MS with and 
without NIR laser irradiation at different pHs. Reproduced with permission.31 Copyright 2012, 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figure 1-7. a) NIR-induced release profiles of DOX from the Dox-GNR@MS@TD aqueous 
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3). Reproduced with permission. 30 Copyright 2015, WILEY-VCH Verlag GmbH & Co. KGaA, 
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(c) Cellular uptake of different sized PCN-224 nanoparticles at various concentrations. Incubation 
time = 24 h. Data are based on ICP analysis of the Zr concentration internalized into HeLa cells. Data 
are means ± s.d. (N = 3). Reproduced with permission.57 Copyright 2016, American Chemical Society.
Figure 2-1. A schematic illustration for light triggered Dox release using the device with the GNR–
Den composite membrane and the bottom pictures indicate each color change in the absence and 
presence of NIR light in the drain passage of the device.
Figure 2-2. Schematic illustration for the formation of a GNR-Den composite membrane, a TEM 
image used in the membrane fabrication, and a SEM image of the composite membrane onto AAO.
Figure 2-3. (a) UV-Vis spectra of a GNR solution (black), dry film (red), and wet film (blue). (b) 
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Apicture of a bare AAO membrane (left) and a GNR-Den composite membrane (right)
Figure 2-4. (a) The temperature traces with and without a GNR-Den film on AAO measured by using 
an infrared camera at a NIR power of 0, 0.18, 0.36, and 0.54 W cm-2. (b) The temperature response 
from the device by NIR irradiation with a power of 0.54 W cm-2.
Figure 2-5. (a) The Dox release profiles for accumulated amounts from the device at NIR powers of 0, 
0.18, 0.36, and 0.54 W cm-2. (b) The Dox release rate profile is based on temperature controlled by a 
NIR power.
Figure 2-6. (a) Schematic illustration of the fluidic system experimental set-up with the GNR-Den 
composite membrane, (b) Dox release profile in the absence (OFF) and presence (ON) of the NIR 
light (850 nm, 0.54 W cm-2, 5 min collection interval), and (c) in vitro cytotoxicity of aliquots 
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Figure 2-3. Molecular structures and their pulsatile release profiles from a mixture of calcein and Rh-
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collection interval).
Figure 2-8. (a) The Dox release percent profile for accumulated amounts from the device at a NIR 
power of 0.54 W/cm2. After 9 hours NIR irradiation at a NIR power of 0.54 W/cm2, the release 
amount was significantly decreased with almost 50% Dox release from the total payload (180 μg) and 
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Figure 2-9. The temperature response from the fluidic device used for the experiment in Figure 5b by 
NIR irradiation (10 min) with a power of 0.54 W/cm2. It shows a little hysteresis in light response. 
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1Chapter 1. Introduction
1.1 Overview
Cancer is one of the world's most dangerous diseases, with 10 million new people suffering from 
cancer each year.1 However, recent studies and understanding of cancer have become more intense, 
and the number of deaths by cancer has been decreasing due to the increased diagnostic and treatment 
sophistication.2 Surgical intervention,3-5 radiation,6-8 and chemotherapeutic drug method9-11 are 
popular therapeutic methods for cancer treatment. These often kill normal cells and induce side 
effects.12 In addition, most cancer drugs are hydrophobic, which pose many problems for 
physiological application12-13. To overcome these problems, nanomedicine has recently been studied to 
improve the stability of hydrophobic drugs through the combination of drugs and nanoparticles.14-15 
Several nanomedicines, USFDA-approved drugs, have been used for treatment (Figure 1-1).16
Figure 1-1. Timeline with some examples of nanoparticles approved by Food and Drug 
Administration.) Doxil® is the liposomal doxorubicin formulation; Feridex® includes 
superparamagnetic iron nanoparticles associated with dextran, DaunoXome® is the liposomal 
daunorubicin, Mylotarg® has gemtuzumab ozogamicin molecules bonded to monoclonal antibody, 
Zevalin® includes mouse monoclonal antibody IgG1 with tiuxetan chelator associated with 
radioactive isotope Yttrium-90, Abraxane® has paclitaxel bonded to albumin; Oncaspar® is the 
modified version of the L-asparaginase enzyme, and Ontak® includes the fusion protein denileukin 
diftitox. Reproduced with permission.16 Copyright 2016, Scientific Electronic Library Online.
2Nanomedicine not only improves drug stability but also selectively transfers the drug to cancer 
cells.17 Nanomedicine can deliver drugs to cancer cells by passive targeting, which accumulates 
selectively in cancer cells according to their size, and active targeting, which targets cancer by 
reacting with substances present on cancer cells and nanoparticles (Figure 1-2).18-21 Passive targeting 
is a method of targeting cancer cells by the enhanced permeability and retention (EPR) effect. Unlike 
normal cells, cancer cells proliferate indiscriminately and promote angiogenesis. Generated blood 
vessels have poorly aligned defective endothelial cells with wide fenestrations, lacking a smooth 
muscle layer, or innervation with a wider lumen.
Figure 1-2. Schematic representation of different mechanisms by which nanomedicine can deliver 
drugs to tumors. Nanomedicine is shown as representative nanocarriers (circles). Passive tissue 
targeting is achieved by extravasation of nanomedicine through increased permeability of the tumor 
vasculature and ineffective lymphatic drainage (EPR effect). Active cellular targeting (inset) can be 
achieved by functionalizing the surface of nanomedicine with ligands that promote cell-specific 
recognition and binding. Nanomedicine can (i) release their contents in close proximity to the target 
cells; (ii) attach to the membrane of the cell and act as an extracellular sustained-release drug depot; 
or (iii) internalize into the cell. Reproduced with permission.23 Copyright 2007, Nature Publishing 
Group.
3These characters induce the higher accumulation of the nanoparticle to the cancer cell than normal 
cells. In particular, nanoparticles are removed by biological barriers, which remove nanoparticles 
greater than 100 nm from the liver and spleen, and nanoparticles of less than 10 nm from the kidney. 
Therefore, nanoparticles having a size of 30-100 nm increase the residence time in the body and 
electively accumulate in cancer cells, potentiating the effects of the cancer drug. 22-26
Active targeting is a method of targeting a cancerous cell by interacting with an overexpressed 
receptor by acting on the nanoparticle surface with a ligand. Methods used for cancer targeting 
include monoclonal antibody, antibody fragment, aptamer, and ligand-based targeting methods.22-26
Although various nanomedicine is used for their ability to target cancer and increase drug stability, 
the low stability of micelle and liposomes in the body make them difficult to encapsulate as drugs27-29
and inorganic nanoparticles have low drug-loading capacity because they depend on covalent bonding 
for drug modification.30-31 In addition, premature release during the drug delivery process causes side 
effects.32-34 To solve these problems, drug delivery systems that respond to stimuli based on porous 
materials have received much interest.
1.2 Porous material for drug delivery.
Gold nanostructure and dendrimer porous material (Den-GNP)
Gold nanoparticles (GNP) and organic compound dendrimers (Den) can be used to synthesize 
porous materials. The gold nanoparticles serve to immobilize the dendrimer, and the dendrimer 
provide space for the drug pathway. These porous materials (Den-GNP) are coated to glass or other 
materials and used for drug or protein control release.35-37
Park et al. demonstrated a system for effectively releasing drugs using Den-GNP porous 
materials.36 These Den-GNP feature release profiles that can be controlled by the dendrimers 
generation and nanoparticle building blocks. In addition, these materials are reusable. The 
encapsulation and release of the drug can be repeated several times using the same porous material 
(Figure 1-3). 
In another paper, Den-GNP was developed to control the various drug release.35 Charge of Den-
GNP was regulated by modifying the functional groups at the end of the dendrimer. These changes 
facilitate controlled release of the drugs and proteins with different charge characteristics (Figure 1-
4b). The porosity of the Den-GNP material can be controlled by changing the dendrimer generation 
providing size-dependent selectivity. In addition, the surface function of Den-GNP can be easily 
modified to control chemo selectivity by charge and hydrophobicity of the membranes, which are 
adjusted after simple functionalization (Figure 1-4b). This porous material improves selectivity for 
analytes based on size, charge and hydrophobicity. As a result, Den-GNP materials facilitate the 
separated release of small molecules, chemicals and biopolymers.
.
4Figure 1-3. Schematic illustration of the formation of Den-NP porous material films and the 
incorporation and release of dyes or drugs and b) an AFM image of Den-GNP porous films on an 
amine-functionalized glass surface. The bottom graph shows the line profile image and a film 
thickness of ≈ 700 nm determined by profilometry. Reproduced with permission.36 Copyright 2011, 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
5 
Figure 1-4. Schematic illustration of fabrication and post-functionalization of hybrid porous material 
membranes. (a) A glass filter, hybrid membrane consisting of Den-GNP composites formed. (b) 
Scheme for post-functionalization within a hybrid porous material membrane to obtain various 
functionalities. Reproduced with permission.35 Copyright 2012, WILEY-VCH Verlag GmbH & Co. 
KGaA, Weinheim.
Mesoporous silica capped gold nanorod (GNR@MS)
Gold nanorod (GNR) is attracting much attention for the bio application of its various features, 
such as high biocompatibility, plasmonic properties, and easy surface functionalization. In particular, 
optical characteristics can be adjusted by controlling the shape of GNR. Using this inherent property, 
absorption of GNR can be tuned in the 700 to 1200 nm range (water window), which is most useful 
for in vivo imaging and treatment, and is widely studied as a photo therapy tool (figure 1-5).38 Despite 
these advantages, the toxicity of the cetyltrimethylammonium bromide (CTAB) bilayer capping the 
GNR surface still has many problems in bio applications. In addition, bare GNR has a low loading 
capacity due to the direct ligand modification between drugs and GNR.30-31 To solve these problems, 
6the GNR surface is coated with organic ligands, small biomolecules, and silica. Among theese, 
mesoporous silica (MS)-coated GNR (GNR@MS) may have the greatest potential as a drug delivery 
system. Mesoporous silica cavities can be used as drug reservoirs, and local heat was generated by the 
surface plasmon resonance (SPR) effect. These inherent properties of GNR@MS facilitate the 
combined chemo & photothermal therapy for effective cancer treatment.39-40
Figure 1-5. a: Synthesis of gold nanorods from spherical gold seeds in the presence of CTAB as a 
shape-directing agent in water at room temperature, showing a cartoon of the final CTAB bilayer. b: 
UV–Vis spectra, transmission electron micrographs, and photographs of aqueous solutions of gold 
nanorods of different aspect ratio (length/width). Aspect ratio increases from left to right. All scale 
bars=100 nm. The yellow shaded area of the spectra is the biological “water window”. Reproduced 
with permission.38 Copyright 2011, Elsevier B.V.
7Zhang et al. have developed a system that enables imaging, chemotherapy, and PTT using GNR@ 
MS (figure 1-6).31 Dos was loaded to the GNR@MS pore by electrostatic interaction. Dox loaded to 
the GNR@MS show the higher cellular uptake ability than free dox. In addition, heat generated by the 
near infrared (NIR) irradiation not only induces drug release but also facilitates photothermal therapy. 
By introducing a heat-responsive gatekeeper system to the GNR@MS, the NIR can be used to turn on 
and off the drug release (figure 1-7). 
Liu et al. have developed a system in which pores of GNR@MS were blocked by thermo-
responsive material, 1-tetradecanol (TD) to control drug release.30 This system facilitates sequential 
drug release by the NIR irradiation. In particular, folic acid was modified to the GNR@MS surface to 
endow the cancer cell-targeting ability. This cancer targeting, and controlled drug release system 
promotes the effects cancer therapy by minimum drug feeding.
Figure 1-6. A) Schematic illustration of GNR@MS as a novel multifunctional theranostic platform 
for cancer treatment. TEM images of B) GNR and C) GNR@MS, D) extinction spectra of GNR, 
GNR@MS, and Dox-GNR@MS, and E) Doxorubicin (Dox) release profiles from Dox-GNR@MS 
with and without NIR laser irradiation at different pHs. Reproduced with permission.31 Copyright 
2012, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
8Figure 1-7. a) NIR-induced release profiles of DOX from the Dox-GNR@MS@TD aqueous 
suspension (100 mg L−1 for Dox-GNR@MS@TD, and ≈84 mg L−1 for GNR@MS) in RPMI-1640 
medium (W/O PR) under NIR light irradiation or external heating, and b) cumulative release of DOX 
from the Dox-GNR@MS@TD aqueous suspension (100 μg mL−1) under multiple NIR light 
irradiation on/off cycle treatment (1.0 W cm−2, 802 nm), while cumulative release profile at 37 °C was 
taken for comparison. The cumulative release was presented as mean value ± standard deviation (n = 
3). Reproduced with permission. 30 Copyright 2015, WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim.
9Metal organic framework (MOF)
Metal organic frameworks (MOF) have been designed through a variety of synthesis strategies and 
have been studied in many areas, such as gas storage41-43 and separation,44-46 catalysis,47-49 and 
sensing.50-52 In recent years, nanosize MOF has received extensive interest as a drug-delivery and 
cancer-therapy system.53
MOFs display a number of advantages over traditional drug carriers. First, the morphology, 
composition, size, and chemical properties of MOF can be tailored for multifunctionalities and 
stimulus-responsive drug release. Second, MOF has a high loading capacity because of its large 
surface area and high porosity. These desirable properties render MOF a promising platform for drug 
delivery and clinical tumor therapy.54 Figure 1-8 show research field of nanomedicine MOF.55
Figure 1-8. Key developments in the nanomedicine applications of NMOFs and NCPs. Reproduced 
with permission.55 Copyright 2015, American Chemical Society.
Figure 1-9. Synthesis of Hf−DBP NMOF and the Schematic Description of Singlet Oxygen 
Generation Process. Reproduced with permission.56 Copyright 2015, American Chemical Society.  
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Recently, Lu et al. have developed a MOF system that enables photodynamic therapy using 
nanoscale MOF (Figure 1-9).56 Photodynamic therapy (PDT) is a type of phototherapy that needs a 
photosensitizer (PS), light source and tissue oxygen to treat the cancer cells. However, most PSs are 
inherently hydrophobic, which induce the PS aggregation and reduce PDT efficacy. To overcome this 
challenge, DBP-UiO, a Hf-porphyrin nanoscale metal-organic framework, was synthesized as an 
effective photosensitizer for PDT. This system has several advantages. First, PS molecules are well 
isolated in framework structure to prevent agglomeration and self-quenching of the excited state. 
Second, porous nano MOF structures provide a pathway that facilitates the diffusion of singlet oxygen 
inside of MOF to increase a cytotoxic effect in the cancer cells.
Figure 1-10. (a) TEM images of PCN-224 nanoparticles of 30, 60, 90, 140, and 190 nm. (b) Cellular 
uptake of PCN-224 samples with different sizes at various incubation time. Concentration = 20 μM. (c) 
Cellular uptake of different sized PCN-224 nanoparticles at various concentrations. Incubation time = 
24 h. Data are based on ICP analysis of the Zr concentration internalized into HeLa cells. Data are 
means ± s.d. (N = 3). Reproduced with permission.57 Copyright 2016, American Chemical Society.
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Parke et al. have developed the PCN-224 synthesis method that controls the size of MOF (Figure 
1-10). 57 The understanding of nanomaterials for targeted cancer therapy is important because it 
relates to cellular responses. Despite the variety of nanomaterials used in these studies, however, there 
was a rare platform that could control the core of nanoparticles at the molecular level. PCN-224 was 
synthesized through a bottom-up approach. The size of MOF nanoparticles has been precisely tuned 
to a wide range with designed functional motifs. In particular, the molecular properties of porphyrin 
linkers, regardless of size, are maintained in MOF nanoparticles. Thus, size-dependent cellular uptake 
and PDT allowed optimal size screening of MOF nanoparticles for PDT, whereas MOF nanoparticle 
formation of photosensitizers showed better PDT efficacy than free PS molecules. In addition, the Zr6 
cluster of MOF further enhanced PDT efficacy by enabling active targeting through post-synthesis 
modification. 
1.3 Thesis summary
In this thesis, we introduce effective cancer treatment using the stimuli-responsive drug system 
based on porous material. 
Chapter 2 describes stable porous materials composed of dendrimers and GNR. This material was 
coated onto the AAP membrane to facilitate controlled drug release by NIR light.  GNR not only 
serves as a dendrimer 's anchor point but also generates heat in response to the 850 NIR laser, which 
belongs to the water window range. Dendrimers maintain structure and provide a pathway for drug 
release. The system can increase the temperature to 52 °C in response to NIR, which can rapidly 
increase the drug release rate. This controlled release allows for more effective cancer treatment by 
maintaining the drug concentration in the therapeutic window.
Chapter 3 describe the dual stimuli responsive system, which consists of mesoporous silica-coated 
GNR (GNR@MS) and glutathione reactive polymer (PEG-PDS). Unlike bare GNR, GNR@MS is 
more effective as a drug delivery system because it has pores for drug loading. However, the loaded 
drug causes an unexpected release during the delivery process, which causes drug side effects. To 
prevent this phenomenon, the pores of GNR@MS was blocked by GSH responsive PEG-PDS. The 
drug is stored stably in the MS cavity by the polymer, and when it reaches cancer cells it is released 
from the nanoparticle because PEG-PDS, which blocks the pore, is degraded by GSH and the pore is 
opened. NIR irradiation also causes the polymer expansion by heat and to induce drug release. This 
dual responsive system can regulate the timing and space of drug release, enabling more effective 
cancer treatment. NIR irradiation causes the polymer expansion inducing the drug release. This dual 
responsive system can regulate the timing and space of drug release, enabling more effective cancer 
treatment.
Chapter 4 describes the hyaluronic-capped PCN-224 MOF system, which can load doxorubicin 
(Dox) for combined therapy. PCN-224 MOF has a higher stability in aqua than other MOFs. The 
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organic linker of PCN (TCPP) is a porphyrinic compound that is widely used as a photosensitizer for 
PDT. Therefore, it is possible to treat chemotherapy by Doxorubicin delivery and PDT by light 
irradiation. HA, that is degraded by HAdase not only controls the drug release but also interacts with 
the overexpressed CD44 receptor on the cancer cell to selectively target the cancer cells. These 
systems facilitate combined therapy and selectively targeted cancer cells to reduce drug side effects 
and improve cancer therapeutic efficacy.
Chapter 5 describes the polyvalent coordination bonds of MOF with polymers, which have the 
carboxylic acid to develop a stable nanomedicine in the body for enhanced cancer treatment 
effectiveness. NanoMOF, which has a high surface, porosity, and easily controllable structure, has 
received much attention in the drug delivery systems. In particular, the unsaturated metal clusters 
present on the surface of MOF can easily form the coordination bond with other compounds for post 
modification. Various nanoMOF drug delivery systems utilize this feature to modify the cancer-
targeting ligand or DNA on the surface of MOF, but a variety of proteins and biocompounds that have 
a Lewis base, and these materials induce the detachment of compounds that modified MOF surface. 
Therefore, in order to prevent above detachment and to increase cancer therapeutic effects, we 
researched stable systems in the body by using a polyvalent coordination bond of MOF with polymer.
Portions of the thesis have been published 
Chapter 2: Kim, K.; Jo, M.C.; Jeong, S.; Palanikumar, L.; Rotello, V. M.; Ryu, J.-H.; Park, M.-H. 
"Externally controlled drug release using a gold nanorod contained composite membrane" Nanoscale,
2016, 8, 11949-11955.
13
1.4 Reference
1. Stewart, B.; Kleihues, P., IARC, World Cancer Report. IARC. Lyon 2003.
2. Society, A. C., Breast cancer facts & figures. American Cancer Society: 2007.
3. Ballard-Barbash, R.; Potosky, A. L.; Harlan, L. C.; Nayfield, S. G.; Kessler, L. G., Factors 
associated with surgical and radiation therapy for early stage breast cancer in older women. JNCI: 
Journal of the National Cancer Institute 1996, 88 (11), 716-726.
4. Laurie, J. A.; Moertel, C.; Fleming, T.; Wieand, H.; Leigh, J.; Rubin, J.; McCormack, G.; Gerstner, 
J.; Krook, J.; Malliard, J., Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of 
levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment 
Group and the Mayo Clinic. Journal of Clinical Oncology 1989, 7 (10), 1447-1456.
5. Singletary, S. E., Surgical margins in patients with early-stage breast cancer treated with breast 
conservation therapy. The American journal of surgery 2002, 184 (5), 383-393.
6. Chithrani, D. B.; Jelveh, S.; Jalali, F.; van Prooijen, M.; Allen, C.; Bristow, R. G.; Hill, R. P.; 
Jaffray, D. A., Gold nanoparticles as radiation sensitizers in cancer therapy. Radiation research 2010,
173 (6), 719-728.
7. D'amico, A. V.; Whittington, R.; Malkowicz, S. B.; Schultz, D.; Blank, K.; Broderick, G. A.; 
Tomaszewski, J. E.; Renshaw, A. A.; Kaplan, I.; Beard, C. J., Biochemical outcome after radical 
prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized 
prostate cancer. Jama 1998, 280 (11), 969-974.
8. Milenic, D. E.; Brady, E. D.; Brechbiel, M. W., Antibody-targeted radiation cancer therapy. Nature 
Reviews Drug Discovery 2004, 3 (6), 488.
9. DeVita, V. T.; Chu, E., A history of cancer chemotherapy. Cancer research 2008, 68 (21), 8643-
8653.
10. Frei III, E.; Canellos, G. P., Dose: a critical factor in cancer chemotherapy. The American journal 
of medicine 1980, 69 (4), 585-594.
11. Matsumura, Y.; Maeda, H., A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. 
Cancer research 1986, 46 (12 Part 1), 6387-6392.
12. Allen, T. M.; Cullis, P. R., Drug delivery systems: entering the mainstream. Science 2004, 303
(5665), 1818-1822.
13. Chowdhary, R. K.; Shariff, I.; Dolphin, D., Drug release characteristics of lipid based 
benzoporphyrin derivative. J Pharm Pharm Sci 2003, 6 (1), 13-9.
14. Doane, T. L.; Burda, C., The unique role of nanoparticles in nanomedicine: imaging, drug delivery 
and therapy. Chemical Society Reviews 2012, 41 (7), 2885-2911.
15. Ranganathan, R.; Madanmohan, S.; Kesavan, A.; Baskar, G.; Krishnamoorthy, Y. R.; Santosham, 
R.; Ponraju, D.; Rayala, S. K.; Venkatraman, G., Nanomedicine: towards development of patient-
14
friendly drug-delivery systems for oncological applications. International journal of nanomedicine 
2012, 7, 1043.
16. Vieira, D. B.; Gamarra, L. F., Advances in the use of nanocarriers for cancer diagnosis and 
treatment. Einstein (São Paulo) 2016, 14 (1), 99-103.
17. Liu, Y.; Miyoshi, H.; Nakamura, M., Nanomedicine for drug delivery and imaging: a promising 
avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 2007,
120 (12), 2527-37.
18. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C., Cancer nanotechnology: the impact 
of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66, 2-
25.
19. Danhier, F.; Feron, O.; Preat, V., To exploit the tumor microenvironment: Passive and active 
tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148 (2), 135-46.
20. Kelso, G. F.; Porteous, C. M.; Coulter, C. V.; Hughes, G.; Porteous, W. K.; Ledgerwood, E. C.; 
Smith, R. A.; Murphy, M. P., Selective targeting of a redox-active ubiquinone to mitochondria within 
cells: antioxidant and antiapoptotic properties. J Biol Chem 2001, 276 (7), 4588-96.
21. Ye, J.; Wang, Q.; Zhou, X.; Zhang, N., Injectable actarit-loaded solid lipid nanoparticles as 
passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008, 352 (1-2), 273-9.
22. Brannon-Peppas, L.; Blanchette, J. O., Nanoparticle and targeted systems for cancer therapy. 
Advanced Drug Delivery Reviews 2012, 64, 206-212.
23. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an 
emerging platform for cancer therapy. Nature nanotechnology, 2007 2 (12), 751-760.
24. Sykes, E. A.; Chen, J.; Zheng, G.; Chan, W. C., Investigating the impact of nanoparticle size on 
active and passive tumor targeting efficiency. ACS Nano 2014, 8 (6), 5696-706.
25. Singh, R.; Lillard, J. W., Jr., Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009, 86
(3), 215-23.
26. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug 
Discov 2005, 4 (2), 145-60.
27. Palanikumar, L.; Choi, E. S.; Oh, J. Y.; Park, S. A.; Choi, H.; Kim, K.; Kim, C.; Ryu, J. H.,
Importance of Encapsulation Stability of Nanocarriers with High Drug Loading Capacity for 
Increasing in Vivo Therapeutic Efficacy. Biomacromolecules 2018, 19 (7), 3030-3039.
28. Palanikumar, L.; Kim, H. Y.; Oh, J. Y.; Thomas, A. P.; Choi, E. S.; Jeena, M. T.; Joo, S. H.; Ryu, 
J. H., Noncovalent Surface Locking of Mesoporous Silica Nanoparticles for Exceptionally High 
Hydrophobic Drug Loading and Enhanced Colloidal Stability. Biomacromolecules 2015, 16 (9), 
2701-14.
29. Chacko, R. T.; Ventura, J.; Zhuang, J.; Thayumanavan, S., Polymer nanogels: a versatile 
nanoscopic drug delivery platform. Adv Drug Deliv Rev 2012, 64 (9), 836-51.
15
30. Liu, J.; Detrembleur, C.; De Pauw-Gillet, M. C.; Mornet, S.; Jerome, C.; Duguet, E., Gold 
nanorods coated with mesoporous silica shell as drug delivery system for remote near infrared light-
activated release and potential phototherapy. Small 2015, 11 (19), 2323-32.
31. Zhang, Z.; Wang, L.; Wang, J.; Jiang, X.; Li, X.; Hu, Z.; Ji, Y.; Wu, X.; Chen, C., Mesoporous 
silica-coated gold nanorods as a light-mediated multifunctional theranostic platform for cancer 
treatment. Adv Mater 2012, 24 (11), 1418-23.
32. Zhang, Q.; Wang, X.; Li, P.-Z.; Nguyen, K. T.; Wang, X.-J.; Luo, Z.; Zhang, H.; Tan, N. S.; Zhao, 
Y., Biocompatible, Uniform, and Redispersible Mesoporous Silica Nanoparticles for Cancer-Targeted 
Drug Delivery In Vivo. Advanced Functional Materials 2014, 24 (17), 2450-2461.
33. Kim, H.; Kim, S.; Park, C.; Lee, H.; Park, H. J.; Kim, C., Glutathione-induced intracellular release 
of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers. Adv Mater 2010, 22
(38), 4280-3.
34. Mura, S.; Nicolas, J.; Couvreur, P., Stimuli-responsive nanocarriers for drug delivery. Nat Mater 
2013, 12 (11), 991-1003.
35. Park, M. H.; Subramani, C.; Rana, S.; Rotello, V. M., Chemoselective nanoporous membranes via 
chemically directed assembly of nanoparticles and dendrimers. Adv Mater 2012, 24 (43), 5862-6.
36. Park, M. H.; Agasti, S. S.; Creran, B.; Kim, C.; Rotello, V. M., Controlled and sustained release of 
drugs from dendrimer-nanoparticle composite films. Adv Mater 2011, 23 (25), 2839-42, 2843.
37. Li, Z.; Huang, P.; Zhang, X.; Lin, J.; Yang, S.; Liu, B.; Gao, F.; Xi, P.; Ren, Q.; Cui, D., RGD-
conjugated dendrimer-modified gold nanorods for in vivo tumor targeting and photothermal therapy. 
Mol Pharm 2010, 7 (1), 94-104.
38. Alkilany, A. M.; Thompson, L. B.; Boulos, S. P.; Sisco, P. N.; Murphy, C. J., Gold nanorods: their 
potential for photothermal therapeutics and drug delivery, tempered by the complexity of their 
biological interactions. Adv Drug Deliv Rev 2012, 64 (2), 190-9.
39. Liu, W.; Zhu, Z.; Deng, K.; Li, Z.; Zhou, Y.; Qiu, H.; Gao, Y.; Che, S.; Tang, Z., Gold 
nanorod@chiral mesoporous silica core-shell nanoparticles with unique optical properties. J Am Chem 
Soc 2013, 135 (26), 9659-64.
40. Shen, S.; Tang, H.; Zhang, X.; Ren, J.; Pang, Z.; Wang, D.; Gao, H.; Qian, Y.; Jiang, X.; Yang, 
W., Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with 
near-infrared radiation. Biomaterials 2013, 34 (12), 3150-8.
41. He, Y.; Zhou, W.; Qian, G.; Chen, B., Methane storage in metal–organic frameworks. Chemical 
Society Reviews 2014, 43 (16), 5657-5678.
42. Ma, S.; Zhou, H.-C., Gas storage in porous metal–organic frameworks for clean energy 
applications. Chemical Communications 2010, 46 (1), 44-53.
43. Mason, J. A.; Veenstra, M.; Long, J. R., Evaluating metal–organic frameworks for natural gas 
storage. Chemical Science 2014, 5 (1), 32-51.
16
44. Chen, B.; Liang, C.; Yang, J.; Contreras, D. S.; Clancy, Y. L.; Lobkovsky, E. B.; Yaghi, O. M.; 
Dai, S., A Microporous Metal–Organic Framework for Gas‐Chromatographic Separation of Alkanes. 
Angewandte Chemie International Edition 2006, 45 (9), 1390-1393.
45. Li, J.-R.; Kuppler, R. J.; Zhou, H.-C., Selective gas adsorption and separation in metal–organic 
frameworks. Chemical Society Reviews 2009, 38 (5), 1477-1504.
46. Li, J.-R.; Sculley, J.; Zhou, H.-C., Metal–organic frameworks for separations. Chemical reviews 
2011, 112 (2), 869-932.
47. Lee, J.; Farha, O. K.; Roberts, J.; Scheidt, K. A.; Nguyen, S. T.; Hupp, J. T., Metal–organic 
framework materials as catalysts. Chemical Society Reviews 2009, 38 (5), 1450-1459.
48. Rogge, S. M.; Bavykina, A.; Hajek, J.; Garcia, H.; Olivos-Suarez, A. I.; Sepúlveda-Escribano, A.; 
Vimont, A.; Clet, G.; Bazin, P.; Kapteijn, F., Metal–organic and covalent organic frameworks as 
single-site catalysts. Chemical Society Reviews 2017, 46 (11), 3134-3184.
49. Zhu, L.; Liu, X.-Q.; Jiang, H.-L.; Sun, L.-B., Metal–organic frameworks for heterogeneous basic 
catalysis. Chemical reviews 2017, 117 (12), 8129-8176.
50. Chen, B.; Wang, L.; Xiao, Y.; Fronczek, F. R.; Xue, M.; Cui, Y.; Qian, G., A luminescent metal–
organic framework with Lewis basic pyridyl sites for the sensing of metal ions. Angewandte Chemie 
International Edition 2009, 48 (3), 500-503.
51. Hu, Z.; Deibert, B. J.; Li, J., Luminescent metal–organic frameworks for chemical sensing and 
explosive detection. Chemical Society Reviews 2014, 43 (16), 5815-5840.
52. Kreno, L. E.; Leong, K.; Farha, O. K.; Allendorf, M.; Van Duyne, R. P.; Hupp, J. T., Metal–
organic framework materials as chemical sensors. Chemical reviews 2011, 112 (2), 1105-1125.
53. Horcajada, P.; Chalati, T.; Serre, C.; Gillet, B.; Sebrie, C.; Baati, T.; Eubank, J. F.; Heurtaux, D.; 
Clayette, P.; Kreuz, C.; Chang, J. S.; Hwang, Y. K.; Marsaud, V.; Bories, P. N.; Cynober, L.; Gil, S.; 
Ferey, G.; Couvreur, P.; Gref, R., Porous metal-organic-framework nanoscale carriers as a potential 
platform for drug delivery and imaging. Nat Mater 2010, 9 (2), 172-8.
54. Wu, M. X.; Yang, Y. W., Metal-Organic Framework (MOF)-Based Drug/Cargo Delivery and 
Cancer Therapy. Adv Mater 2017, 29 (23).
55. He, C.; Liu, D.; Lin, W., Nanomedicine Applications of Hybrid Nanomaterials Built from Metal-
Ligand Coordination Bonds: Nanoscale Metal-Organic Frameworks and Nanoscale Coordination 
Polymers. Chem Rev 2015, 115 (19), 11079-108.
56. Lu, K.; He, C.; Lin, W., Nanoscale metal-organic framework for highly effective photodynamic 
therapy of resistant head and neck cancer. J Am Chem Soc 2014, 136 (48), 16712-5.
57. Park, J.; Jiang, Q.; Feng, D.; Mao, L.; Zhou, H. C., Size-Controlled Synthesis of Porphyrinic 
Metal-Organic Framework and Functionalization for Targeted Photodynamic Therapy. J Am Chem 
Soc 2016, 138 (10), 3518-25.
17
Chapter 2. Externally controlled drug release using a gold nanorod 
contained composite membrane.
2.1 Abstract
Versatile drug delivery devices using nanoporous membranes consisting of gold nanorods and 
dendrimers have been demonstrated to provide light-triggered on-demand pulsatile release from a 
reservoir containing highly enriched therapeutics for a real patient’s needs. The drug release rate is 
directly correlated with the temperature increase and irradiated energy of a near-IR laser in both static 
and fluidic devices. This biocompatible platform for on-demand control was further confirmed by in 
vitro experiments. Interestingly, different responses to stimuli were obtained from each drug in the 
absence and presence of NIR light, indicating the versatile potential of our on-demand drug delivery 
system in less-invasive therapies requiring multi-drug delivery strategies. The enhanced delivery 
system will improve therapeutic efficacy and reduce side effects through regulation of plasma drug 
profiles.
2.2 Introduction
Biomaterials with stimuli-responsive properties, also known as smart materials, have the unique 
ability to alter their chemical or physical properties for applications in optoelectronics, sensors and 
actuator devices, surface coating, storage, and drug delivery applications.1-3 The responsiveness of 
these biomaterials can be changed or tuned in a reproducible and predictable manner through 
chemical, biological, and physical stimuli. These responses can be generated by a number of stimuli 
relating to the properties of scaffolds for example solvent dissolution, pH, ionic strength, and 
temperature, and response to external fields for example near-infrared, visible light, ultrasound, or 
electric and magnetic fields, and molecular functions for example receptor recognition and 
enzymemediated reactions.4-11 The Stimuli-responsive biomaterials are critical in the province of drug 
delivery because of the difficulty in sustaining an effective therapeutic range of the drugs over a 
defined period of time to avoid overdosing or underdosing.12-15 Additionally, many drugs require 
frequent and continuous administration over long periods.16-18 Finally, the ability of drug delivery 
systems to be manipulated externally and programmed spatially and temporally within the desired 
therapeutic window provides an important tool to satisfy the needs of a patient.19-22 However, only a 
few studies have been applied in commercial clinical settings because delivering pulsatile or variably 
programmed drug release patterns in an easy manner has not been well studied yet.23
A light-activated drug delivery system provides several benefits such as ease of control, locally 
selective exposure, and harmlessness to body tissues.24-26 Near-infrared (NIR) light, in the range from 
650 and 900 nm, provides a particularly useful avenue because hemoglobin and water strongly absorb 
infrared light (>900 nm) and visible (<650 nm), respectively, leaving the NIR as a window.27-29
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Plasmonic materials are particularly promising for these applications: NIR light can penetrate body 
tissues at a depth of 10 cm over with no significant damage, inducing localized heat at a NIR 
wavelength corresponding to the plasmonic resonance of the contained nanoparticles, called the 
photothermal effect.30-36
Recently, we reported a dendrimer-nanoparticle composite film formed via dithiocarbamate (DTC) 
crosslinking of small gold nanoparticles in the presence of carbon disulfide (CS2).
37,38 This 
biocompatible, highly flexible composite film is capable of delivering various molecules such as 
biologics and drugs, enabling the controlled release of therapeutics and the design of devices capable 
of sustained release. We report here the use of a nanoporous membrane consisting of gold-nanorods 
(GNRs) and dendrimers that enables on-demand pulsatile release from a reservoir containing highly 
enriched therapeutics. These light-responsive GNR-dendrimer (GNR-Den) composites generate 
localized heat around the GNRs in the membrane when stimulated with NIR light. The increasing heat 
of the membrane increases the diffusion coefficient, accelerating the release rate of drugs and 
ultimately enabling high-resolution control of drug release based on the patient’s state (Figure 2-1).
Figure 2-4. A schematic illustration for light triggered Dox release using the device with the GNR–
Den composite membrane and the bottom pictures indicate each color change in the absence and 
presence of NIR light in the drain passage of the device.
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2.3 Results and discussion
The GNR–Den films were formed via chemical reaction by DTC crosslinking between dendrimers 
and GNRs (60 nm length and 15 nm width) capped with cetyltrimethylammonium bromide (CTAB). 
The films were coated on the both sides of amine-functionalized anodized aluminum oxide (AAO) 
membrane having hexagonally packed cylindrical nano-channels with uniform pore sizes with a 
diameter of 20 nm.40 The image of scanning electron microscopy (SEM) and picture of membranes 
indicate the successful formation of a smooth composite film with a thickness of ∼0.7 μm on an 
AAO membrane (Figure 2-2 & Figure 2-3b). The GNR-Den film was fabricated on a slide glass 
substrate and characterized by ultraviolet-visible (UV-Vis) spectroscopy to determine the optical 
properties. As shown in Figure 2-2b, the black line indicates the typical longitudinal plasmonic band 
of the original CTAB-GNRs, while a strong red shift (the red line) is seen in the dry state after film 
formation due to the decrease in the interparticle spacing between GNRs.41 In an aqueous solution, the 
composite film containing highly permeable dendrimers can be extended because of solvent swelling, 
causing an increase in distance between the chemically assembled GNRs and concomitant with blue 
shift in the UV-Vis spectrum (the blue line) (Figure. 2-3a). 
Figure 2-5. Schematic illustration for the formation of a GNR-Den composite membrane, a TEM 
image used in the membrane fabrication, and a SEM image of the composite membrane onto AAO.
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Figure 2-6. (a) UV-Vis spectra of a GNR solution (black), dry film (red), and wet film (blue). (b) 
Apicture of a bare AAO membrane (left) and a GNR-Den composite membrane (right)
The fabricated GNR-Den-AAO membrane was fitted between polydimethyl siloxane(PDMS) 
replicas to form a programmable passage for drug supplies from a reservoir (Figure 2-1). Diffusion is 
the process of the kinetic energy by which molecules and particles randomly blend together, leading 
to a phenomenon where they move from an area of high concentration to an area of low concentration. 
The rate of diffusion is affected by several factors including temperature, density of the diffusing 
substance, medium of diffusion, and concentration gradient. Among them, temperature is a key factor 
for diffusion that can be explicated using the Stokes-Einstein-Sutherland equation.
          (1)
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where D is the diffusion constant, μ is the mobility of particles, kB is Boltzmann’s constant, and T 
is the absolute temperature. For diffusion of spherical particles through a liquid, η is the dynamic 
viscosity and R is the radius of the spherical particle. In addition, as the temperature increases, the 
average kinetic energy of molecules increases, and the increased kinetic energy causes increased 
velocities, providing a greater chance of collisions between molecules and resulting in an increased 
rate of diffusion. Therefore, the delivery mechanism with our device based on diffusion should be 
strongly related to temperature, both due to basic diffusion parameters and changes in the 
thermoresponsive membrane.42
Figure 2-7. (a) The temperature traces with and without a GNR-Den film on AAO measured by using 
an infrared camera at a NIR power of 0, 0.18, 0.36, and 0.54 W cm-2. (b) The temperature response 
from the device by NIR irradiation with a power of 0.54 W cm-2.
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To validate our hypothesis, temperature traces of the device containing a GNR-Den membrane 
upon NIR irradiation were recorded first using an infrared camera (Figure 2-4a). In the absence of 
NIR light, normal room temperature (21.6 and 21.5 °C) was observed in the device with and without a 
GNR-Den membrane, respectively. Upon continuous NIR irradiation, the device with a GNR-Den 
composite membrane showed the increased temperature of 28.8, 41.0, 51.9 °C depending on the 
energy (0.18, 0.36, 0.54 W cm-2, respectively) of the irradiated NIR light (λ= 850 nm). No significant 
change in temperature was observed in the device without a composite membrane (22.4 °C) (Figure 2-
4a).
Figure 2-8. (a) The Dox release profiles for accumulated amounts from the device at NIR powers of 0, 
0.18, 0.36, and 0.54 W cm-2. (b) The Dox release rate profile is based on temperature controlled by a 
NIR power.
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Figure 2-4b shows the kinetic thermal response of the composite membrane by NIR irradiation with 
the energy 0.54 W cm-2. The rapid increase from 21.4 to 40 °C was seen within 10 s while a gradual 
increase was observed from 10 to 200 s. Because the thermal response of the GNRs upon NIR 
irradiation has been known to be much faster,43 we assume that the temperature increase measured by 
using an infrared camera includes the water content in a drug reservoir. After investigating 
temperature response upon NIR irradiation, doxorubicin hydrochloride (Dox) was chosen as a model 
drug to investigate the on-demand release feature of the membrane. Figure 2-5 shows the cumulative 
amounts of Dox released from the reservoir. With the same concentration of Dox solution (850 μM, 
0.4 mL) in the reservoir, on-demand, zero-order release was achieved that was directly correlated to 
the power of NIR irradiation. Release rates of 3.5, 5.5, and 8.2 μg h-1 were obtained with light powers 
of 0.18, 0.36, and 0.54 W cm-2, respectively, while low release (0.5 μg observed in a control 
experiment with no NIR. These results indicate a h-1) was direct relationship between the amounts of 
released drugs, temperature, and irradiated light energy, suggesting an efficient strategy for on-
demand controlled release. To demonstrate the robustness of our membrane, the collected aliquots 
from the accumulated drain layer after 3, 9, 12, and 36 hours in the presence of NIR light and 336 
hours in the absence of NIR light were further analyzed using ICP-Mass. The negligible signals (<1 
μg L-1) concerning gold (267.594) observed with each sample indicate that our GNR-Den membrane 
in devices is robustly retained during light stimuli. We next integrated our membrane into a
continuous flow system. The GNR-Den-AAO membrane was fitted into a PBS flow system consisting 
of PDMS channel and peristaltic pump, just as shown in Figure 2-5a. With a continuous PBS flow (4 
mL h-1) each fraction was collected for every 5 min. Figure 2-5b shows the Dox amounts of each 
fraction as analyzed using UV-Vis spectroscopy and a fluorimeter. Strikingly, rapid and strong release 
of Dox from the fluidic device was observed upon NIR irradiation, while slow release was shown in 
the absence of NIR light. This reversible phenomenon can be obtained continuously when the switch 
is ON/OFF and also utilized for the patients who unexpectedly require a high flux of drugs. After 
successfully demonstrating the light-triggered release of drugs through the GNR-Den membrane, we 
further investigated the ability to efficiently regulate drug amounts in cancer cells cultured in in vitro 
experiments. SCC-7 cancer cells were treated with drug aliquots collected in the presence of NIR 
irradiation (40 min (NIR1) and 120 min (NIR2)) and in the absence of NIR irradiation (80 min 
(NoLight1) and 160 min (NoLight2)), and cell viability was determined after 48 h and 72 h using 
alamar blue dye assay. The cell viability assays with both aliquots collected in the presence of NIR 
light revealed that Dox delivery significantly decreased cell viability to lower than 25% and 10% after 
48 h and 72 h, respectively, whereas a relatively small decrease in the viability (to approximately 60-
75%) was observed with the aliquots collected in the absence of NIR light (Figure 2-6c). These results 
suggest that our GNR-contained membrane can be used to control on-demand release of therapeutics 
based on the conditions of patients who require doses of drugs frequently and precisely.
24
Figure 2-9. (a) Schematic illustration of the fluidic system experimental set-up with the GNR-Den 
composite membrane, (b) Dox release profile in the absence (OFF) and presence (ON) of the NIR 
light (850 nm, 0.54 W cm-2, 5 min collection interval), and (c) in vitro cytotoxicity of aliquots 
collected at 80 (NoLight1) and 160 min (NoLight2) with no irradiation and at 40 (NIR1) and 120 min 
(NIR2) with NIR irradiation after 48 h and 72 h incubation.
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For example, the minimum drug concentration in a therapeutic range has been retained usually 
depending on individual patients, however when the necessity arises, it becomes accelerated by 
switching ON for NIR irradiation to provide a high dosage. Previously, our research group has 
demonstrated the effectiveness of post-functionalized composite membranes in controlling the 
diffusion rate based on the analyte charge, porosity, and hydrophobicity.44 The functionalized 
composite membrane capable of interacting with each analyte more selectively can efficiently control 
the diffusion rate of the analytes. We assumed that because both the prior and current systems are 
based on a diffusion release mechanism, the functionalized membrane will also provide multi-drug 
releases with programmable pharmacokinetics in a delivery system. This means our system can 
provide a controlled concentration for each drug in an each therapeutic range of relevance through not 
only an initial feeding ratio of multi drugs but also their chemical structure. 
Figure 1-10. Molecular structures and their pulsatile release profiles from a mixture of calcein and 
Rh-6G from the TMA-GNR-Den membrane contained fluidic device (850 nm, 0.54 W cm-2, 2.5 min 
collection interval).
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As a proof-of-concept of a multi-drug delivery system with different pharmacokinetics, the 
positively charged composite membrane was utilized with two watersoluble organic dyes (anionic 
calcein and cationic rhodamine 6G (Rh-6G)) with opposite charges but similar structures. The 
positively charged trimethyl ammonium (TMA)-functionalized membrane was fabricated by the post-
functionalization method previously mentioned15 and fitted into the fluidic device. With a continuous 
PBS flow (4 mL h-1) each fraction was collected for every 2.5 min. Initially, the different 
concentrations of two dyes were observed before NIR irradiation despite the same feeding ratio (Rh-
6G:calcein=1:1), because the positively charged TMA membrane interacted more strongly with 
anionic calcein, which retarded its release, than with cationic Rh-6G. However, different diffusion 
responses were observed in the presence of NIR light (Figure 2-7). The localized heat caused by NIR 
irradiation accelerated the release rate of both dyes as mentioned above. Interestingly, Rh-6G weakly 
interacted with the TMA membrane showing a much faster release (7 times higher than before 
irradiation), while a comparatively small acceleration of calcein release (3 times higher than before 
irradiation) was observed because of their strong reciprocal interaction with the TMA membrane 
(Figure 2-7). Overall, the difference in concentration was two times in the absence of NIR light, but it 
becomes 4.5 times in the presence of NIR light. This phenomenon can be efficiently used when the 
release of multi-drugs is limited to different therapeutic ranges for each drug, opening a new way with 
our versatile platform.
2.4 Summary
The versatile platform presented in this study provides NIR triggered drug release using a GNR-
contained membrane. The direct correlation ship between NIR energy and the drug release rate makes 
the system readily programmable for pulsatile release. We incorporated the membrane into a device 
containing a refillable drug reservoir for sustained release. Proof of concept biological studies using 
SCC-7 cancer cells demonstrate the potential utility of this system for therapeutic release. 
Interestingly, different responses to stimuli were obtained from each drug in the absence and presence 
of NIR light, indicating the versatile potential of our on-demand drug delivery system in less-invasive 
therapies requiring multi-drug delivery strategies. These enhanced delivery systems have the potential 
to improve therapeutic efficacy and reduce side effects through regulation of plasma drug profiles, 
providing a new direction in the design of implantable medical devices that combine microscale and 
macroscale technologies.
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2.5 Experimental
Table 2-1. ICP-Mass data from each collected aliquot from the accumulated drain layer after 3(#1), 
9(#2), 24(#3), and 36 hours(#4) in the presence of NIR light at a power of 0.54 W/cm2 and 336 
hours(#5) without NIR light. The results indicate that our GNR-Den membrane in the device is 
robustly retained during light stimuli.
Figure 2-8. (a) The Dox release percent profile for accumulated amounts from the device at a NIR 
power of 0.54 W/cm2. After 9 hours NIR irradiation at a NIR power of 0.54 W/cm2, the release 
amount was significantly decreased with almost 50% Dox release from the total payload (180 μg) and 
reached a plateau during next 18 hours even in the presence of NIR. (b) The Dox release percent 
profile for accumulated release amounts from the device in the absence of NIR for a long time period.
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Figure 2-9. The temperature response from the fluidic device used for the experiment in Figure 2-6b 
by NIR irradiation (10 min) with a power of 0.54 W/cm2. It shows a little hysteresis in light response. 
The media in the drug reservoir have been slowly heated with light and rapidly cooled without light, 
because the continuous water flow under the membrane in the fluidic device could be acted like a 
cooling system. We observed the fast increase in 10 sec up to 40 °C, but the slow increase to 50 °C 
after next 10 min because the media in the drug reservoir have been heated together by the localized 
heat from GNRs in the presence of light. With no heat source in the absence of light, the continuous 
supply of fresh PBS rapidly cooled the media in drug reservoir, showing fast decease in drug release 
rate.
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Materials and methods: Cetyltrimethylammonium bromide (CTAB), Gold(III) chloride trihydrate 
(HAuCl4·3H2O), Sodium borohydride (NaBH4), ascorbic acid (AA), Silver nitrate (AgNO3), 
rhodamine B (Rh-B), calcein, and doxorubicin (Dox) were purchased from Aldrich and used any 
further purification. The Sylgard 184 silicone elastomer kit, anodic aluminum oxide (AAO) 
membranes (Anodisc 25, 60 μm film thickness and 0.02 μm pore size), and a peristaltic pump were 
purchased from the Fisher Scientific. A diode laser system with a wavelength of 850 nm and 2000 
mW output power was used for a light stimulus. Temperature traces were recorded using a Ti95 an 
infrared camera (Fluke, USA). Scanning electron microscopy and transmission electron microscopy 
images were acquired on a JSM-6510, JEOL, Japan, and JEOL 1000CX operating at 80 keV 
respectively. The concentration of the drugs that were transferred through the membrane was 
measured using QM-400 spectrofluorometer (PTI, USA) and Neosys-2000 a UV-Vis 
spectrophotometer (Scinco, USA). The concentration of gold in a drain layer was analysed using the 
ELAN DRC-II ICP-Mass (Perkin Elmer, USA). For in vitro cell study, squamous cell carcinoma 
(SCC-7) cancer cells were purchased from American Type Culture Collection. Dulbecco’s Modified 
Eagle’s Medium (DMEM, Sigma Aldrich), fetal bovine serum (FBS, Thermoscientific), and 
antibiotics (Cellgro) were prepared. Phosphate buffered solution 1X (PBS) was purchased from 
Thermo Scientific. Photoluminescence was analyzed on a Photon Technology International 
fluorescence spectrometer with Felix 32 and cell viability was determined on a Spectra-Max M5 
microplate reader (Molecular Devices). 
Preparation of GNRs: The CTAB coated GNRs were prepared along a known procedure using a 
seed-mediated growing method.39 In a typical procedure, 0.5 mL of an 10 mM solution of HAuCl4
was added to 15 mL of a aqueous 10 mM CTAB solution, followed by mild stirring until the solution 
became brown-yellow. Subsequently, 1.2 mL of an 10 mM NaBH4 aqueous solution was quickly 
added with rapidly stirring until the solution turned brown-yellow. The temperature of the seed 
solution was maintained at 25 °C before use. A 10 mM aqueous solution of AgNO3 (0.36 mL) was 
added to a mixture of an 10 mM solution of HAuCl4 (2.4 mL) and a 100 mM solution of CTAB (57 
mL) in a 50 mL Falcon tube with gentle stirring. Subsequently, 0.384 mL of 100 mM AA was added 
and the aqueous solution became colorless following addition and gently mixing of AA. Finally, 0.12 
mL of the seed solution was rapidly added, and the reaction solution was mixed slowly for 10 s and 
left undisturbed state for at least 8 h in a water bath. The GNR solution was purified by centrifugation 
at 13,000 rpm repeatedly. The shape and size of the prepared GNRs were confirmed with TEM.
Fabrication of the device and characterization of drug release: A polydimethylsiloxane (PDMS) 
replica was fabricated by mixing a 10:1 (v/v) mixture of the Sylgard 184 elastomer and a curing 
reagent using a extremely flat silicon wafer channel mold. The mixture was cured for 4 h at 80 °C and 
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then shuck from the mold. After the fabrication of the PDMS channel mold, a GNR-Den-AAO 
composite membrane was fitted into the middle of the PDMS replica and then covered with another 
PDMS replica to form the PDMS device. After gently placing the device in a fresh phosphate buffered 
solution (PBS), a Dox-enriched solution (0.4 mL, 850 μM) was poured into a reservoir placed over 
the membrane (Figure 2-1a). During continuous agitation, 1 mL fractions in the drain were collected 
for an intended period and analyzed using UV-Vis spectroscopy. After collecting each fraction, 1 mL 
of fresh PBS was added to retain the PBS level in the drain. To prepare the fluidic device, one side of 
the device was linked to a peristaltic pump, which supplied a continuous flow of PBS (pH = 7.4), and 
the other side was fitted with sample collection containers for fluorescence quantification of the 
released drugs (Figure 2-4). The flow rate of PBS was retained at 4 mL h−1 by using the peristaltic 
pump. After 10 min of initial flowing for wetting of a GNR-Den membrane, the samples were 
collected after passing through the channel including the Dox-enrich reservoir. The release profiles of 
Dox from the reservoir under both conditions were generated by analyzing the collected PBS samples 
over time using a fluorescence spectrometer. 
Post-functionalization of a GNR–Den membrane: Post-functionalization of a GNR-Den membrane 
was easily achieved by placing the membrane in a solution for each reactant with mild stirring. In a 
typical experiment, the prepared GNR-Den membrane was immersed into a solution of 0.5 mM HCl 
solution for 3 h to regenerate initial amine groups onto PAMAM dendrimers. This NH2-membrane
was further placed in a 100 mL methanol solution of MeI (1.0 mL) in the presence of triethylamine 
(1.0 mL) for 12 h. After rinsing with methanol several times, the TMA-membrane was dried 
completely before experiments.
In vitro analysis: SCC-7 cells were cultured in RPMI 1640 supplemented with 10% FBS and 1% 
antibiotics under a humidified atmosphere of 5% CO2 at 37 °C. Cells were seeded at 2 × 105 cells per 
wells in a 96-well plate for 24 h. SCC-7 cells were cultured with each sample for 48 h or 72 h in a 
CO2 incubator at 37 °C. Cell viability was estimated by an alamar blue assay (alamarBlue®, AbD 
Serotec, UK). After 48 h or 72 h of incubation, the cells were washed three times with PBS and then 
incubated with fresh culture medium supplemented with 10 vol% alamarBlue® solution. Following 
the incubation, 0.10 mL of medium from each well was transported into a 96-well plate. Fluorescence 
was assessed (excitation 560 nm and emission 590 nm) by a microplate reader.
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Chapter 3. Dual responsive drug release of polymer coated GNR@MS
nanoparticle for cancer therapy.
3.1 Abstract
Nanoparticles has been considerable as a drug delivery system to deliver hydrophobic drugs. 
However, premature drug release during the delivery process, occurs drug side effect. To overcome 
this challenge, we developed a stimuli responsive gatekeeper system. This system blocks the pore to 
keep the drug in the nanoparticle and open the pore by responding to internal (pH, enzyme, hypoxia, 
redox) or external stimuli (temperature, sonication, magnetic, light). The system responding to 
internal and external signals can regulate the space and timing of drug release, increasing the effects 
of cancer therapy. Glutathione (GSH) polymer-coated gold nanorod (GNR) mesoporous silica (MS) 
core shell structure (GNR@MS) respond to the internal and external stimuli and can control the drug 
release.  In particular, GNR@MS increases the cancer therapy effect by combined chemo and 
photothermal therapy.
3.2 Introduction
Nanoparticles facilitate the delivery of hydrophobic drugs and selective cancer accumulation 
through the EPR effect.1 However, as a result of low encapsulation stability, a significant amount of 
the loaded drug is released upon circulation, and the drug cannot be readily released from the 
nanoparticle after reaching the target cancer cell. Recently, gatekeeper systems have been studied to 
control the release of drugs to prevent unexpected drug release during drug delivery, to reduce the 
side effects and increase the therapeutic effect.2-6 Gatekeeper system blocks the nanoparticle pores by 
a stimuli-responsive material to control the drug release..5-6 Drug release in these systems is controlled 
by internal stimuli (pH, enzyme, hypoxia, redox) and external stimuli (temperature, sonication, 
magnetic, light).7-9 These internal stimuli-responsive materials have the advantages of self-controlled 
drug release and facile application in clinical settings at the targeted cancer cell.10-11 The external 
stimuli-responsive nanoparticles, on the other hand, offer obvious merits of precision space and 
timing as well as dose control over drug release through a remote apparatus, in which drug release 
might be switched on and off at will.12-13 Thus, internal stimuli enable spatial control and external 
stimuli enable temporal control. The system responding to internal and external signals can regulate 
the spatial and temporal of drug release, increasing the cancer therapy effect.7, 14-17
We developed PEG-PDS-coated gold nanorod (GNR) mesoporous silica (MS) core shell structure, 
a GNR@MS@PDS dual-stimuli system. The drug encapsulation was induced bynoncovalent 
interaction such as the Van der waals interaction, and physical absorbance.18-19 Theporous MS shell 
induces an increase in loading capacity as the interaction with the drug increases. GNR@MS shows 
higher drug loading capacity than drug modification of GNR.20-21 Thus, GNR@MS induces the local 
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temperature increase by the surface plasmon resonance (SPR) effect under the near infrared (NIR) 
light irradiation. Increasing the temperature not only promotes drug release by inducing drug diffusion 
but also facilitates photo thermal therapy (PTT) by generating heat.22 The PEG-PDS used to block the 
open pore of the nanoparticle is degraded by glutathione (GSH). Therefore, GNR@MSN@PDS 
induces drug releases in response to GSH (internal) and light (external) stimuli.18, 20, 23 In addition, 
chemo and photothermal combined therapies increase the cancer cell therapy effect (Figure 3-1).
Figure 3-1. Schematic illustration of preparation of GNR@MS@PDS and dual-stimuli responsive 
chemo and PTT combined therapy procedure.
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3.3 Results and discussion
GNR@MS was synthesized according to a reported protocol.24 Synthesized GNR showed that 
length and width were respectively 37 nm and 12 nm (aprox. 3:1 aspect ratio). After coating the silica 
to the GNR, 10 nm thickness of mesoporous silica shell (MS) was observed in TEM image (Figure 3-
2b). Comparing the absorption band of GNR, the absorption band of GNR@MS red sifted about 30 
nm upon the silica coating (Figure 3-2a). This phenomenon is explained by the fact that the local 
refractive index of the silica shell is larger than that of water. 
GNR@MS can be used as a drug-delivery system because it can load drugs to a MS shell. Dox 
loading capacity was 5% when the concentration of supernatant was calculated by Beer's law after
loading GNR@MS. After loading Dox to the GNR@MS, polymer-coated GNR@MS (GNR@ 
MS0@PDS) was synthesized according to a reported protocol.20 For polymer coating, Pyridine of 
PEG-PDS polymer was protonated by the added hydrochloric acid. Protonated pyridine endows the 
plus charge to the polymer that facilitates the approach of polymer to the GNR@MS surface. After 
attachments of polymer, Dithiolthreitol (DTT) was added to immobilize the polymer on the 
nanoparticle surface. The morphology of GNR@MS@PDS was confirmed by TEM and had a core 
shell morphology of GNR@MS.
Meanwhile, the surface charge of GNR@MS@PDS was increased from -35.0 mV to -22.4 mV 
after polymer coating (Figure 3-2c). These results suggest that the polymer was well-coated on the 
nanoparticle surface without destruction of structure. Coated polymer with a disulfide bond is 
selectively cleaved by GSH. Synthesized GNR@MS@PDS exhibits an SPR effect under light stimuli 
and increases the temperature in the surrounding solution. Figure 3-2d shows the temperature change 
of the GNR@MS@PDS.  As the concentration of GNR increased so did the maximum temperature 
of the solution, with a maximum temperature of 58°C at 0.8 nM. The maximum temperature increases 
as a linear function of the nanoparticle concentration (Figure 3-2e). 
PEG-PDS polymer-coating prevents the unexpected release of drugs by blocking the pores and 
increases the biocompatibility of nanoparticles. Drug-loaded GNR@MS@PDS facilitates the 
controlled drug-release in response to GSH and light stimuli. As shown in Figure 3-2f, encapsulated 
drugs are released in the presence of GSH or light irradiation. Meanwhile, Dox release is effectively 
prevented in absence of stimuli. GSH induces the degradation of the polymer that blocks the pore of 
GNR@MS and facilitates drug release. Light stimuli that leads to local temperature increase induces 
the drug release by polymer swelling. Thus, GNR@MS@PDS effectively regulates drug release in 
response to dual stimuli. 
Dox-loaded GNR @MS@PDS was cultured in SCC7 cells for 3 hours, and the cell uptake ability 
was confirmed by observing the location of the nanoparticles using a confocal microscope. As shown 
in Figure 3-3a, Dox fluorescence well colocalize with Lysotracker, suggesting the existence of in the 
lysosome by the endocytosis of the cell.
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Figure 3-2. Characterization of GNR@MS@PDS a) UV-visible spectra for GNR and GNR@MS; b) 
TEM images of GNR@MS; c) Zeta potential measurements of GNR@MS and GNR@MS@PDS; d); 
e) heat generation effect of GNR@MS at different concentration; f) Drug release profile analysis in 
presence and absence of light and GSH.
Figure 3-3. Cellular uptake analysis for Dox loaded PGNRMS in SCC7 cells at different time points 
of incubation. Uptake pathway analysis for Dox-PGNRMS in presence of uptake pathway inhibitors b) 
Sucrose - caveolae, b) amilorin – macropinocytosis and c) methyl beta cyclo dextrin
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To confirm the cellular uptake pathway, GNR@MS@PDS was added to cells pretreated with 
various inhibitors, namely sucrose (clathrin-mediated uptake), methyl-beta cytodextrin (caveolae 
mediated uptake) and amilorin (macropinocytosis). An inhibitor-treated SCC7 cell was incubated with 
a Dox-loaded nanoparticle for 3 hours, after which a methyl beta cytodextrin and amilorin pretreated 
cell line showed a strong Dox fluorescence. Meanwhile, a sucrose-treated cell showed low 
fluorescence, suggesting that the cellural uptake mechanismof GNR@MS@PDS relates with clathrin-
mediated uptake pathway (Figure 3-3b). 
To verify the biocompatability and PTT effect, GNR@MS@PDS, calceinAM, and ethdiumbromide 
was incubated to the scc7cell. Living cells show green fluorescence by Calcein AM and dead cells 
show red fluorescence by propidium iodide (PI). As shown in Figure 3-4, the control displayed a 
green fluorescence regardless of light irradiation. On the other hand, red fluorescence was increased 
when light was irradiated to GNR@MS@PDS incubated cell, suggesting that nanoparticles treat the 
cancer cell by inducing PTT under the light irradiation. In order to investigate the effect of cancer 
treatment by controlled drug release, SCC-7 cells were incubated with GNR@MS@PDS and Dox-
loaded GNR@MS@ PDS for 24 hours.  
Figure 3-4. a) Laser irradiation-mediated apoptosis measured by PI/calcein staining assay after 
incubation for 12h in SCC7 cells for GNR@MS in presence and absence of laser. b) Cell viability 
analysis for Dox loaded GNR@MS@PDS nanoparticles in SCC7 cells in the presence and absence of 
laser irradiation after 24 h incubation, nanoparticles were incubated for 12h, replaced and wash with 
fresh media. Laser power set at 1.6 W/cm2 for 5 min
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As shown in Figure 3-4b, the drug-free GNR@MS@PDS showed low toxicity up to 0.1 nM 
concentration and treated cancer cells in the presence of light irradiation. This implies that the PTT 
effect was induced by light irradiation. The drug-loaded GNR@MS@PDS was found to be toxic 
without light irradiation because the polymer is cleaved by GSH and releases the drug to enable 
chemotherapy. Dox-loaded GNR@MS@PDS was shown the toxicity in absence light irradiation, 
implying that the drug was released from the nanoparticle because of polymer degradation by the 
GSH. Furthermore, under light irradiation, the cancer cell therapy effect was increased by chemo and 
photodynamic-combined therapy.
3.4 Summary
In summary, we developed the internal and external stimulus responsive gatekeeper system on 
GNR@MS for combined chemo & photothermal therapy. GNR coated with MS facilitates Dox 
loading through physical adsorption due to the increased surface area of nanoparticles. The PEG-PDS 
polymer blocks the pore of the MS to prevent premature release of the drug. Drug release of the 
GNR@MS@PDS system was triggered by responding the GSH and NIR light irradiation. Invitro 
experiment show the increased therapy effect by combined chemo and photo thermal therapy. Thus, 
our GNR@MS@PDS, dual stimuli responsive controlled drug release system increases the cancer 
therapy effect. 
3.5 Experimental
General information: All chemicals and reagents were purchased from Sigma-Aldrich, TCI and Alfa 
Aesar, Korea unless otherwise specified and used without further purifications. Doxorubicin 
hydrochloride was obtained from Ontario Chemicals Inc, Canada. Deionized (DI) water was produced 
by the Millipore Milli-Q system (18.2 MΩ cm).
Synthesis of PEG−PDS Random Copolymer: The PEG−PDS random copolymer was synthesized 
using the RAFT polymerization method. In detail, 2-cyano-2-propyl benzodithioate (0.05 mmol), 
PDSEMA (3.92 mmol), poly(ethylene glycol) methacrylate (0.98 mmol), and AIBN (0.0146 mmol) 
were mixed together in a round-bottom flask containing THF and degassed by purging with Ar under 
sealed condition. Under constant stirring at 70 °C for 24 h, the samples were collected, precipitated 
thrice in ice-cold diethyl ether, and vacuum-dried. The synthesized samples were analyzed by NMR 
spectroscopy. 
Synthesis of mesoporous silica capped gold nanorod (GNR@MS): GNR@MS were synthesized 
according to a reported protocol.24 0.25 mL of an aqueous 10 × 10−3 M solution of HauCl4 was added 
to 7.5 mL of a 10 × 10−3 M CTAB solution, followed by gentle stirring until the solution became 
bright brown-yellow. Subsequently, 0.6 mL of an aqueous 10 × 10−9 M NaBH4 solution was quickly 
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added with vigorous stirring until the solution turned pale brown-yellow. The temperature of the seed 
solution was retained at 25 °C before use. A 10 × 10−3 M solution of AgNO3 (0.18 mL) was added to 
a mixture of an aqueous 10 × 10−3 M solution of HAuCl4 (1.2 mL) and a 100 × 10
−3 M solution of 
CTAB (28.5 mL) in a 50 mL Falcon tube with mild stirring. Subsequently, 0.192 mL of 100 × 10−3 M 
AA was slowly added and mixed, after which it became colorless. After addition of 0.06 mL of the 
seed solution, the reaction mixture was gently mixed for 10 s and left undisturbed for at least 8 h in a 
water bath at 35 °C. After 8 h, the as-synthesized GNR was centrifuged and washed with Milli-Q 
water twice at 11,000 rpm for 25 min to remove excess CTAB. Then, the precipitate was redispersed 
in 100 mL of DI water followed by adding 1 mL of NaOH (0.1 M) solution. Thereafter, 300 µL 
TEOS/MeOH (20%, v/v) was injected three times under gentle stirring at 30 min intervals. After 
gentle stirring for another 6 h, GNR@MS was obtained and washed with DI water twice to remove 
the unreacted species.
Syntehsis of PEG-PDS modified GNR@MS: GNR@MS were capped using the PEG−PDS 
copolymer following method. About 0.1 ml of GNR@MS was dispersed in 0.9 mL of DI water 
containing 10 mg of PEG−PDS polymer and continuously stir for a period of 12 h at room 
temperature. To cross-link the polymer shell, partial amount of DTT was added (50 mol % against 
PDS group) and again stir for a period of 3 h at RT to allow in situ cross-linking. Then the polymer 
capped GNR@MS were collected by centrifugation, washed thrice with DI water. 
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Chapter 4. MOF X Biopolymer: Collaborative Combination of Metal-
Organic Framework and Biopolymer for Advanced Anticancer Therapy.
4.1 Abstract
Metal-Organic Framework (MOFs) nanoparticles with high porosity and greater tunability have 
emerged as new drug delivery vehicles. However, premature drug release still remains a challenge in 
MOF delivery system. Here, we report enzyme responsive polymer coated MOF gatekeeper system 
using hyaluronic acid (HA) and PCN-224 nanoMOF. The external surface of nanoMOF can be stably 
covered by HA through multivalent coordination bonding between Zr-cluster and multiple carboxylic 
acid of HA, which acts as a gatekeeper. HA allows the selective accumulation of drug carriers in 
CD44 overexpressed cancer cells and the enzyme response drug release in the cancer cell 
environment. In particular, inherent characteristics of PCN-224, which is used as a drug carrier, 
facilitate transfer the drug to cancer cells more stably and allows photodynamic therapy. This HA-
PCN system enables dual therapy of chemotherapy and photodynamic therapy to enhance cancer 
therapy effect.
4.2 Introduction
Cancer is a public health threat worldwide, responsible for 609,940 deaths in the United State alone 
in 2018.1 Although chemotherapy is a popular cancer treatment therapy, direct administration of 
anticancer drugs often causes severe side effects.2 Development of drug delivery vehicles, which 
regulate drug release while minimizing side effects and maintaining therapeutic efficacy, is highly 
desirable.3-5 Drug delivery systems have developed for the past few decades include inorganic 
mesoporous silica,6 quantum dots,7 metal nanoparticles,8-10 polymer nanoparticle11 and organic 
dendrimers.10, 12 However, these systems are still far from ideal drug delivery systems, difficult to 
satisfy the following important requirements simultaneously, including large drug loading capacity, 
colloidal stability, low toxicity, and bio-degradability.13-15  
Metal-organic frameworks (MOFs), a new class of porous materials, are now emerging as new drug 
delivery vehicles,16-18 due to their high porosity and their greater tunability compared to conventional 
porous materials,19, 20 providing multifunctionalities based on size,20 composition,21 topology22, 23 and 
chemical properties.24, 25 However, controlled drug release has not been investigated extensively in 
these MOF-based systems.26, 27 Most of reported nanoMOFs has lack of colloidal stability in aqueous 
environment and premature drug release behavior even without any stimuli as the surface of 
nanoMOFs is not fully covered. To stably deliver drug molecules into cancer cells without undesired 
drug leakage before reaching target site and increase therapeutic effect by releasing the drug 
molecules inside the cancer cells, it is necessary to regulate drug release precisely by introducing the 
stable stimuli-sensitive system into the surface of nanoMOFs.
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To achieve this goal, we design an enzyme responsive polymer gatekeeper on nanoscale MOF 
(nanoMOF). First, we choose a nanoscale, Zr-based porphyrinic MOF, PCN-224, for a main 
component for the drug delivery system.28 This MOF is robust, yet biodegradable, with large surface 
area, and stable over wide range of pH.29 Furthermore, it can generate 1O2, an essential feature for 
photodynamic cancer therapy.30 After loading drug molecules inside MOF, the nanoscale MOFs are 
covered with a gatekeeper, blocking the pore entrance to preserve drug molecules inside the pore to 
prevent premature release.31, 32 Hyaluronic acid (HA), a natural polysaccharide with good 
biocompatibility, is chosen as a polymer gatekeeper. NanoMOFs covered with HA gatekeeper several 
significant advantages; (i) the multiple coordination bonds between HA and the MOF make stable 
surface modification and keep the drug molecules inside pore, ii) hydrophilic HA on the MOFs 
provides a good colloidal stability in the water, (iii) HA acts as a cancer-targeting ligand for selective 
drug delivery because it can interact with CD44 which is overexpressed in many cancer cells, and (iv) 
HA is degraded by HAdase in cancer cells so that the drug molecules can be only released inside the 
cancer cell. We hypothesize that such a carefully designed HA-nanoMOF system would be a highly 
efficient drug delivery system for multimodal anticancer therapy. Herein, we report that HA-
nanoMOF system loaded with anticancer drug doxorubicin (Dox) is indeed highly efficient for cancer 
therapy. This approach is one step closer to precision medicine, providing multifunctional capabilities, 
including cancer-targeting, on-site drug release, and photodynamic therapy (Figure 4-1). This 
combined therapy,33, 34 chemotherapy and PDT, demonstrated here is highly efficient for targeting 
multi-drug resistant cancer cells. 
Figure 4-1. Illustration of preparation of HA gate keeper metal organic frame work nanosystem and 
chemo and PDT combined therapy procedure
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4.3 Results and discussion
The crystal structure of PCN-224 has a she topology with Im-3m space group which contains three-
dimensional open channels with 1.9 nm.28 As biocompatibile Zr (IV) has strong interaction with the 
carboxylate linker, Zr nodes provide the framework robustness and thus ensures that the drug is 
delivered to cancer cells stably. In addition, the porphyrinic linker in the MOF framework allows 
efficient PDT without aggregation in the aqua solution. PCN-224 nanoparticles were synthesized 
using a synthetic method described in the previous report.30 Synthesized PCN-224 nanoparticle was 
observed spherical morphology with 100 nm by TEM and SEM (Figure 4-2a, b). The structure of 
synthesized nanoparticles was confirmed by powder X-ray diffraction (PXRD). Experimental PXRD 
pattern of the MOF nanoparticle is well matched the PCN-224 simulation (Figure 4-2c) and still 
maintains crystallinity after HA coating, implying MOF structure remain during the synthesis process. 
The nanoMOF has a large Brunauer-Emmett-Teller (BET) surface area of 2296(8) m2/g and three-
dimensional channels with 1.8 nm pore size those were measured by N2 adsorption studies at 77K 
(Figure 4-2d, 4-5). This high surface area and porosity allow the drug loading in large quantities, 
demonstrating the potential of the PCN-224 nanoparticle as a drug delivery carrier. We investigated 
the loading capacity of the hydrophobic Dox in unmodified PCN-224 through physical entrapment. 
The drug encapsulation mechanism is caused by noncovalent interactions such hydrogen bonding and 
van der Waals interactions, allowing the high surface area of PCN-224 to interact more effectively 
with the drug molecule.48 As showing in Figure 4-6, PCN-224 shows high loading capacity ability 
(108%, weight ratio between Dox and nanoMOFs).
Figure 4-2. a) TEM and b) SEM image of PCN-224 that size is around 90nm. c) PXRD pattern of 
PCN-224 (graph change to arbitrary unit) d) N2 sorption data of PCN-224 e) DLS size of PCN-224 
and HA-Dox-PCN. f) Surface charge was measured by Zetasizer  
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Along with major limitation in MOF drug delivery system, the hydrophobicity of the particle surface 
and opened pore of Dox-PCN can cause low colloidal stability and premature drug release. To 
overcome such drawbacks, the Dox-PCN has been modified by HA biopolymer through the 
coordination interaction with Zr cluster and carboxylic acid of HA. The DLS experiment indicated an 
increase in the hydrodynamic radius of HA-Dox-PCN (~250 ± 20 nm) compared with that of PCN-
224 (~164 ± 20 nm) (Figure 4-2e). After HA coating, MOF still have the spherical morphology 
(Figure 4-7). Furthermore, surface properties of PCN-224 and HA-Dox-PCN were measured by zeta 
potential in aqueous solution. The zeta potential experiment indicated a change of the surface charge 
from positive potential of PCN-224 (+27 mV) to negative potential of HA-Dox-PCN (-34 mV) 
(Figure 4-2f). Size and surface charge change indicate that HA was coated successfully on PCN-224 
surface. HA-Dox-PCN colloidal stability was studied by measuring the size change by varying the 
time in media. 
Figure 4-3. a) HA-Dox-PCN colloidal stability measured by DLS in cell media over 48 h. b) 
Modified HA amount to PCN at different concentration of NaCl. c) Fluorescence titration graph d) 
Enlarged snapshots of interacting structures between HA decamers and PCN-224 surface with water 
molecules. Black dashed lines represent hydrogen bond. e) Energy diagram of the reaction path on the 
formation mechanism of coordination bond between HA monomer and Zr6 cluster model in surface 
region. The acronyms IS, TS, IM and FS represent the initial, transition, intermediate and final states, 
respectively. The numbers represent the relative energies of each state based on that of the IS. f) 
Atomic configurations of each state in reaction coordinate. The atoms in bond formation reaction are 
shown by ball-and-stick, while the remaining atoms are presented by sticks. Except for water 
molecule colored in blue, the Zr, C, H, and O atoms are colored in cyan, gray, white, and red, 
respectively.
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As shown Figure 4-3a, particle size didn’t show any significant different for 48 h, indicative of high 
colloidal stability. NP colloidal stability is important for the safe and effective nanomedicine since 
low colloidal stability of NPs can lead to capillary blockage in vivo and are likely to be rapidly 
removed by the body's reticuloendothelial system (RES).
There are two possible driving forces of HA coatings; i) by electrostatic interactions since the 
highly negative charged HA can interact with the highly positive surface potentials of PCN-224, ii) by 
the coordination bond of HA with Zr-cluster. To investigate the main driving force of HA-coating, we 
observed the effect of salt concentration in HA-coating process. We hypothesized that if the main 
driving force is the electrostatic interaction, the coating of HA onto PCN-224 will be influenced by 
ionic strength of the solution, since increasing ionic strength weaken the electrostatic interactions. 
Modified amount of HA was confirmed at different sodium chloride concentrations by the carbazole 
assay, which is commonly used to measure the amount of HA.
As shown in Figure 4-3b, the amount of HA is independent on the concentration of sodium chloride. 
More interestingly, the HA coating is quite satbleeven at high salt concentration (2 M). These results 
imply that the coating of HA might be happened by the coordination bonds, along with simple 
electrostatic interaction. To further investigate binding between HA and PCN-224, fluorescence 
titration was performed.49 Different molecular weight of FITC-modified HA (high molecular weight 
HA (1,500~2,200 kDa), and low molecular weight HA (8~15 kDa) ) were prepared to compare the 
binding constant. The fluorescence of FITC-modified HA (FITC-HA) was significantly quenched 
when PCN-224 nanoparticles were added, probably due to the energy transfer from FITC to porphyrin 
framework (Figure 4-3c, Figure 4-8). The normalized fluorescence intensities of FITC-HA at 520 nm 
were plotted against the ratio of nanoparticle to polymer. The binding constants (Ks) were obtained 
through nonlinear least-squares curve-fitting analysis. Ks of high molecular weight HA-FITC with 
PCN-224 is 2.9 x 1011 M-1. Meanwhile, that of low molecular weight HA-FITC with PCN-224 is 
significantly decreased to 3.19 x 107 M-1. These results suggest that number of carboxylate groups of 
HA affect to the binding force. Therefore, polyvalent coordination bonds with Zr-clusters on the 
surface of PCN-224 nanoparticle is very important for a robust and stable gatekeeper system.
HA-coating on nanoMOF, we observed physical adsorption of HA on the surface of PCN-224 via 
molecular dynamics simulations. (see Theoretical methods). At the low HA coverage systems with 2 
decamers in the coating layer in the dry and hydrated conditions, HA’s became adsorbed along the 
pore edge of the PCN-224 due to the formation of hydrogen bonds (Figure 4-12). However, as the 
number of HA decamers increased to 6 to thickening the HA-coating, amorphous coating layer was 
formed, resulting in the blocking of pore structure in nanoMOF. More specifically, at the outermost 
surface of nanoMOF with HA’s in the dry condition, -OH in HA (e.g. carboxylic acid and hydroxyl 
group) stably interacted with terminal hydroxyl group of the Zr6 nodes (Figure 4-13a) and amine
group of the TCPP linkers. 
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Even in the hydrated condition, similar molecular configuration was observed while the hydroxyl 
groups and the water molecules interacting with each other, as shown in the Figure 4-3d and 4-13b,
contributing to stably locating HA-coating layer near the surface. We conjectured the formation of 
coordination bond between HA and nanoMOF would be driven by this strong hydrogen bonding force.
To verify the formation of coordination bond between HA and Zr6 node, thermodynamic 
mechanism was calculated via density functional theory (DFT) calculation (Figure 4-3e, f and 4-14). 
By considering molecular configurations observed at hydrated condition in MD simulation, HA 
monomer and water molecule were placed near the terminal -OH group of the Zr6 cluster. To make 
coordination bond between HA and nanoMOF, we assumed that the reaction would occur at the 
structure interconnected by hydrogen bonding interactions, i.e. water molecule, carboxyl acid in HA, 
and terminal -OH group of the Zr6 cluster. At the initial reaction, hydrogen atom was transferred from 
carboxylic acid in HA to terminal -OH group in Zr6 node, which was stabilized by adjacent water 
molecule. Subsequently, remaining carboxylate was coordinated to open Zr site, accompanying 4.16 
kcal/mol of activation energy (Ea), and -6.63 kcal/mol of heat of reaction(∆E). From IM1 to FS, as-
made water molecule was readily detached from Zr atom, and concurrently carboxylate was 
coordinated to the Zr atom with 9.42 kcal/mol of Ea and -13.25 kcal/mol of ∆E. Considering this 
relatively low Ea, if the HA polymer was closely located to the Zr6 metal node of the PCN-224, the 
polymer was expected to construct new coordination bond with the PCN-224 even at room 
temperature.50 
Due to high expression of HAdase in cancer cells, the gatekeeper, HA can be degraded inside 
cancer cells to trigger the release of the drug molecules. We first monitored HA degradation by 
HAdase in aqueous solution by observing the change of the surface charge. As shown in Figure 1f, the 
surface charge of HA-PCN was changed from -34 mV to +4 mV after incubation with HAdase. This 
indicates that coated HA on the PCN-224 was degraded by HAdase. HAdase triggered drug release 
was investigated by measuring the emission of released Dox from HA-Dox-PCN. 
As shown Figure 4-4a, when HAdase (400 U/ml) was added to the HA-Dox-PCN aqueous 
suspension after 3h incubation, Dox fluorescence intensity was gradually increased, implying that 
HAdase induce the drug release by degrading the HA which attached to PCN-224 surface. Meanwhile, 
only HA-Dox-PCN indicated stable encapsulation of Dox without unwanted drug release. It suggests 
that HA efficiently blocked the PCN-224 pore entrance before degradation by HAdase. 
To facilitate the dual therapy, we chose the water stable PCN-224 consisting of Zr and porphyrinic 
organic ligand which is used as a sensitizer for photo dynamic therapy. The (4-carboxyphenyl) 
porphyrin photosensitizer that constitutes PCN-224 can make use of the light to produce 1O2. 1O2
generation was investigated by measuring ABDA absorption decrease under photo-irradiation.  As 
shown Figure 4-4b and 4-17, ABDA absorbance consistently decreases by increasing illumination 
time. Additional advantage of HA coating is selective targeting cancer and controlled drug release by 
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HAdase inside the cancer cells. The cancer targeting ability is confirmed by monitoring cellular 
uptake experiments. Prepared HA-Dox-PCN was incubated with Hek 293T (Human embryonic 
kidney 293 cells, CD44 negative cell), MDA-MB-231 (human mammary gland -breast cancer cells), 
and SCC7 ((Murine squamous cell carcinoma, CD44 positive cells). After 2h incubation, cellular 
uptake ability of HA-Dox-PCN was observed by confocal microscopy. MDA-MB231 and SCC-7 cell 
was shown higher intensity of Dox compare with Hek 293T cell (Figure 4-4c). It is well known that 
CD44 is over expressed on the surface of cancer cell. Thus, these results suggest that HA-Dox-PCN 
nanoparticles can selectively uptake into CD44 receptor expressing cancer cells. Cellular uptake 
pathway experiment was conducted to confirm the more accurate invasion mechanism of HA-Dox-
PCN. Figure 4-16 shows that cellular uptake of HA-Dox-PCN is associated with clathrin mediated 
endocytosis. The therapy effect of PCN, HA-PCN, and HA-Dox-PCN were investigated by measuring 
cellular viability. Hek 293T (CD44 negative), MDA-MB-231(CD44 positive), and SCC-7(CD44
positive) cell was incubated with PCN-224, HA-PCN, and HA-Dox-PCN. Only PCN-224 showed 
toxicity to CD44 negative cells under light irradiation (Figure 4-4d, 4-18). Meanwhile, HA-PCN 
showed toxicity under light irradiation in CD44 positive cells (Figure 4-19). In addition, HA-Dox-
PCN showed increased toxicity in existence light irradiation (Figure 4-4e, 4-20). These results suggest 
that HA facilitate the selective cancer cells uptake and combined chemo-photodynamic therapy 
increase the cancer therapy effect under light irradiation. Furthermore, MCF-7/ADR cell (multidrug-
resistant (MDR) human breast cancer) was prepared to observe the HA-Dox-PCN therapy effect in 
the MDR cell. MCF-7/ADR cell show low cell viability when incubate with HA-Dox-PCN with light 
irradiation (Figure 4-21).
Figure 4-4. a) Drug release profile of HA-Dox-PCN. b) ABDA assay analysis of PCN-224 and HA-
Dox-PCN. c) Confocal imaging to check the cellular uptake of Dox loaded HA-PCN nanoparticles 
after 2h incubation. Cell viability analysis at different cell line at PCN-224 5 µg/ml d) Hek 293T, e) 
MDA-MB-231
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4.4 Summary
In summary, we developed the enzyme responsive polymer gatekeeper system on nanoMOF for 
combined chemo & photodynamic therapy. NanoMOF, PCN-224, has very high loading capacity for 
hydrophobic Dox through physical adsorption due to a large surface area of nanoMOF. The polymer 
gatekeeper, HA blocks the pore entrance to preserve drug molecules inside the pore and prevent 
premature release through polyvalent coordination bonds along with electrostatic interaction. Drug 
release of HA-Dox-PCN system was triggered by responding HAdase enzyme stimulation and can 
specifically target the cancer cells. In vitro experiment of combination chemo and photodynamic 
therapy showed higher therapeutic efficacy under the light irradiation. Moreover, this system 
effectively treats the MCF-7/ADR drug resistant cell compare dox chemotherapy. Thus, our HA-Dox-
PCN, controlled drug release system, expand role of the nanoMOF as drug carrier.
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4.5 Experimental
Figure 4-5. a) N2 sorption and b) pore size distribution of PCN. 
Figure 4-6. 100times diluted supernatant UV-Vis spectra after drug loading to PCN (Initial dox 
concentration is 8 mg/mL in DMSO).  
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Figure 4-7. TEM image of HA-Dox-PCN nanoparticle that size is around 90 nm
Figure 4-8. a,b) Fluorescence titration graph ( HA molecular weight: 8,000 ~ 15,000 )
53
Figure 4-9. a) Slab models of PCN-224 MOF. Fragmented Zr6 cluster model in b) bulk and c) surface 
region. d) Fragmented TCPP ligand cluster. For the clear view, the slab model is presented by space-
filling model, whereas cluster models are presented by ball-and-stick. The Zr, C, H, O, and N atoms 
are colored in cyan, gray, white, red, and blue, respectively.
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Figure 4-10. Atomic type representation of PCN-224 (see Table 4-1). Color scheme is same as Figure 
4-9.
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Table 4-1. Partial charges for atomic types in PCN-224 (as labeled in Figure 4-10).
Atom Charge (e) Atom Charge (e)
C1 0.600 H1 0.317 
C2 -0.032 H2 0.290 
C3 -0.088 H3 0.373 
C4 -0.097 H4 0.112 
C5 0.035 H5 0.069 
C6 0.047 H6 0.071 
C7 0.160 H7 0.248 
C8 -0.132 O1 -0.938 
Zr 1.964 O2 -0.792 
N1 -0.260 O3 -0.702 
N2 -0.410 O4 -0.600 
Hs (Surface) 0.171 Os (Surface) -0.742 
56
Figure 4-11. Initial models employed in MD simulations. Slab models with a) 2, b) 4, and c) 6 HA 
decamers. Slab models with d) 2, e) 4, f) 6 HA decamers in hydrated condition. For the clear view, the 
slab models are presented by space-filling model, whereas HA decamers are shown by stick with each 
different color (from orange to purple). Water molecules are presented by transparent blue space-
filling model. Color scheme of the atoms in the slab models is same as Figure 4-9. 
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Figure 4-12. Equilibrated structures of HA-coating on PCN-224 surface after 3ns MD simulations. 
Slab models with a) 2, b) 4, and c) 6 HA decamers. Slab models with d) 2, e) 4, f) 6 HA decamers in 
hydrated condition. Color scheme and presented styles are same as Figure 4-11. 
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Figure 4-13. Enlarged snapshots of interacting structures between HA decamers and PCN-224 surface 
a) without and b) with water molecules. Black dashed lines represent hydrogen bond. For the clear 
view, some selected atoms are shown by ball-and-stick to show hydrogen bonding between HA and 
PCN-224 with water. Except for these atoms, all atoms are shown by stick, and color scheme is same 
as Figure 4-11. 
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Figure 4-14. Extended atomic configurations of the formation mechanism of coordination bond 
between HA monomer and Zr6 cluster model in surface region. The acronyms IS, TS, IM and FS 
represent the initial, transition, intermediate, and final states, respectively. Except for water molecule 
in blue, all atoms are presented by stick, and color scheme is same as Figure 4-9. 
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Figure 4-15. Confocal microscope images of of HeK 293T, MDA-MB-231 and SCC7 to check the 
cellular uptake of HA-Dox-PCN nanoparticles after 2h incubation.
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Figure 4-16. Confocal microscope images of SCC7 cells incubated in presence of uptake pathway 
inhibitors to check the uptake pathway of HA-Dox-PCN nanoparticles after 2h incubation. 
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Figure 4-17. ABDA assay analysis of a) PCN-224 and b) HA-Dox-PCN for checking singlet oxygen 
generation. c) Absorbance decrease of ABDA by generation of singlet oxygen d) d) ABDA reaction 
mechanism with singlet oxygen. 
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Figure 4-18. Cell viability analysis of PCN at different cell line a) Hek 293T, b) MDA-MB-231, and c) 
SCC7.
Figure 4-19. Cell viability analysis of HA-PCN at different cell line a) Hek 293T, b) MDA-MB-231, 
and c) SCC7.
Figure 4-20. Cell viability analysis of HA-Dox-PCN at different cell line a) Hek 293T, b) MDA-MB-
231, and c) Scc7.
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Figure 4-21. Cell viability analysis of HA-Dox-PCN at MCF-7/ADR cell a) free Dox, b) HA-Dox-
PCN.
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Material and method
General information: All chemicals and reagents were purchased from Sigma-Aldrich, TCI and Alfa 
Aesar, Korea unless otherwise specified and used without further purifications. Sodium hyaluronate 
was purchased from Acros Organic (Belgium). Doxorubicin hydrochloride was obtained from Ontario 
Chemicals Inc, Canada. Deionized (DI) water was produced by the Millipore Milli-Q system (18.2 
MΩ cm).
Preparation of PCN-224 (100 nm): PCN-224 nanoparticles were synthesized in a solvothermal 
condition as reported.30 Meso-Tetra(4-carboxyphenyl)porphine (TCPP) (100mg, 0.13mmol), 
ZrOCl2·8H2O (300mg, 0.93mmol), benzoic acid (2.8g, 23mmol) and DMF (100mL) were combined 
in a 250mL round-bottom flask. The mixture was heated to 90 °C for 5hours with 300rpm stirring and 
then cooled to room temperature. The product was collected by centrifugation with 15000rpm for 
30min and washed by fresh DMF and acetone. The synthesized PCN-224 sample was characterized 
by powder X-ray diffraction (PXRD).
Characterizations of PCN: Before gas adsorption measurement, 90 nm-PCN-224 samples were 
thoroughly washed with DMF for three times and acetone for twice. After decanting acetone, samples 
were dried under vacuum for 3 hours. And the dried powder was activated at 85 °C for 30 min and 
120 °C for 5hours on ASAP 2020 for N2 adsorption measurement. BET surface area for PCN-224 is 
2296(8) m2/g. Corresponding pore size distribution was analyzed by the non-local density functional 
theory (NLDFT).
Preparation of Dox-PCN: About 4 mg of PCN-224 were dispersed in 8mg of Dox were dissolved in 
1 mL of DMSO and stir for 24 hours at room temperature. Then the Dox loaded PCN-224 was 
collected by centrifugation and dried under high vacuum. Then dried samples were redispersed in DI 
water. The supernatant solution containing unloaded Dox were analyzed under UV-Visible spectra 
using molar absorption coefficient.
Drug loading capacity (%): Mass of the drug in PCN-224/Mass of PCN-224 * 100
Preparation of HA-Dox-PCN: About 1 mg of Dox loaded PCN were dispersed in 20 mL of DI water 
containing 2 mg of Hyaluronic acid (HA) and stir for 24 hours at room temperature. Then HA coated 
Dox-PCN was collected by centrifugation and redispersed in DI water. HA-Dox-PCN was washed 3 
times by repeated centrifugation and redispersion. The supernatant solution containing unmodified 
HA were analyzed by carbazole assay.  
Synthesis of Amine modified FITC: Amine functional group was modified to fluorescein 
isothiocyanate (FITC) to prepare FITC-HA. FITC (5 mg, 12 μmol) and ethylenediamine (1 μL, 18 
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μmol) were dissolved in 2 mL of DMSO. The mixture was stirred at room temperature for 12 hours. 
The solvents and ethylenediamine was removed by freeze drier. 
Synthesis of FITC-HA: Hyaluronic acid (20 mg) was dissolved in 10 mL of DI water. Then, EDC 
(15mg, 97 μmol) and NHS (11mg, 96 μmol) was added in HA solution. The mixture was stirred at 
room temperature for 4 hours. Then, Amine modified FITC (2.2 mg, 5 μmol) was added in the 
mixture solution. After stirring at room temperature for 24 hours, the mixture was purified by dialysis 
by using 2.5K dialysis bag for 1 week. After dialysis, solution was removed by the freeze drier. 
Drug Release Profile: Release kinetics of HA-Dox-PCN was analyzed by Shimadzu RFPC 5430 
spectrophotometer. Nanoparticle was dispersed in phosphate-buffered saline (pH 7.4). After 
dispersion, Dox fluorescence intensity was measured on a at excitation wavelengths of 480 nm. To 
determine the induced drug release profile, HAdase (400 U/ml) was added to the nanoparticle solution 
at 4 hours and the release profile was analyzed using a fluorescence.
Singlet oxygen generation analysis: Newport IQE-200 solar simulator (Irvine, CA, USA) was used 
as a light source. The power density for light was 40 mW/cm2. To measure the generated singlet 
oxygen (1O2), 9,10-anthracenediyl bis(methylene)malonic acid (ABDA) and nanoparticle (100 μM 
and 20 μM) was prepared in distilled water. The absorbance of ABDA is attenuated after reaction 
with 1O2 from PCN-224. The degree of absorbance changes before/after photo-irradiation implies 
absolute amount of generated 1O2. Absorbance was obtained for every 2 minutes under the irradiation.
Binding constant analysis: 1 mL HA-FITC solution (2.5 nM) was placed in the vial. Different volume 
of PCN-224 (8.55 nM) and D.I water were subsequently added to the HA-FITC solution. Mixture 
solution volume adjust to 3 mL. Emission spectrum of sample was recorded with excitation at 470 nm. 
After measurement, The normalized fluorescence intensities calibrated by respective controls  at 520 
nm were plotted against the concentration of PCN-224. Nonlinear least-squares curve-fitting analysis 
was conducted to estimate the complex stability.
Cell culture: Murine squamous carconoma cell SCC-7, Human breast cancer cell lines MDA-MB-
231, Human breast cancer MCF-7/ADR cells and non-cancerous fibroblast HeK293T cells were 
obtained as a gift from Prof. Sebuyang Kang lab at UNIST and Prof. Ick Chan Kwon at KIST, Korea. 
The cells were cultured (using RPMI 1640 and DMEM medium, respectively) while supplemented 
with 10% fetal bovine serum (FBS), 100 µg mL-1 streptomycin and 100 U mL-1 penicillin under 
incubation at 37 °C and humidified with 5% CO2.
Cell viability analysis: Cells (5 × 103 cells/well) were cultured in sterile 96-well Nunc (Thermo 
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Scientific Inc.) plates for 24 hours and treated with different concentrations of PCN, HA-Dox-PCN 
(1.0, 2.0, 3.0, 4.0 and 5.0 µg/mL) for 12 hours in dark, then media was replaced with fresh media and 
the cells were irradiated for 30 min at 1 sun light (100 mW cm-2 ) using the solar simulator. Cells were 
incubated for another 12 hours before checking the cell cytotoxicity using Alamar blue dye assay 
following the manufacturer’s protocol (DAL 1025, Invitrogen).
Endocytic pathway analysis: To check the endocytosis mediated uptake pathway of HA-Dox-PCN, 
MDA-MB231 cells were seeded in four well chambered cover glass (Lab Tek II, Thermo Scientific 
Inc.) and pretreated with different inhibitors including sucrose (clathrin-mediated uptake, 400 nM), 
methyl-beta cytodextrin (caveolae mediated uptake) and amilorin (macropinocytosis) in serum-free 
DMEM for 1 hour and replaced with fresh media. 35 Afterwards, HA-Dox-PCN were added to the 
medium for another 1 h incubation. Then the cells were analyzed under the confocal microscope 
(Olympus FV1000) connected to CO2 incubator.
Cellular uptake analysis: The cellular uptake of HA-Dox-PCN nanoparticles in HeK293T, MDA-
MB-231 and SCC-7 cells were investigated by live confocal microscope images (Olympus FV 1000 
series). The cells were seeded at a density of 2 x 105 cells/well in two well chambered cover glass 
(Lab Tek II, Thermo Scientific. After 24 hours incubation, cells were treated with HA-Dox-PCN at a 
final concentration of Dox at 10 µg/mL at different time points and analyzed using the confocal 
microscope. 
Theoretical methods
Molecular modeling: To investigate the interfacial structure between HA-coating and PCN-224 
surface via molecular dynamics (MD) simulation and density functional theory (DFT) calculation, we 
modelled two kinds of model systems for PCN-224 MOF, i.e. slab and cluster models. Each model 
was taken from crystal structure of PCN-224, which was obtained from experimental XRD analysis. 
For the charge balance around the Zr(IV) atom, half of μ3-OH and μ-OH in each Zr6 node were 
substituted by μ3-O and μ-H2O, respectively, as suggested by Park et al.’s work.30 The slab model was 
modeled as thin monolayer slab perpendicular to (100) surface, which was composed of 8 Zr6 nodes 
and 8 TCPP ligands, with about 70 Å of vacuum region (Figure 4-9a). Dangling bonds and charge 
imbalance due to (100) surface cleavage were compensated by adding two hydroxyl groups to each 
Zr6 node, i.e. (Zr6(μ3-O)4(μ3-OH)4(μ-OH)8(μ-H2O)6)8TCPP8. For the cluster model, we employed 3 
fragmented cluster models to represent the structure around Zr6 node in the bulk and surface regions 
as well as TCPP ligand, respectively (Figure 4-9b-d). The TCPP ligand was so bulky that it was 
replaced by carboxy phenyl functional group in Zr6 cluster. Thus, the Zr6 cluster model in bulk region 
68
was composed of Zr6(μ3-O)4(μ3-OH)4(μ-OH)6(μ-H2O)6(C6H5COO)6, whereas that in surface region 
was composed of Zr6(μ3-O)4(μ3-OH)4(μ-OH)8(μ-H2O)6(C6H5COO)4. These cluster models were 
employed for calculating partial charges of PCN-224 (Figure 4-10 and Table 4-1), and for calculating 
formation mechanism of coordination bond. 
Molecular Dynamics: To observe physical adsorption of HA polymers on nanoMOF, we employed 
slab model and HA decamer, whose length was about 2 to 3 times longer than one side of the slab 
model. In the MD simulation, we modelled HA-MOF systems with three different numbers of HA 
decamers (i.e.  2, 4, and 6 HA decamers, respectively) near one side of the surface (Figure 4-11). In 
addition, to apply hydrated condition in HA-coating, hydrated models were also considered, where 
water molecules were packed in all void region of each system. In the MD simulation, the PCN-224 
slab was regarded as a rigid body, whereas HA and water molecules were free to move. To observe 
relaxed configuration of HA, we carried out thermal annealing in the range of temperatures between 
298K and 500 K for 3 ns. For the non-bonding interaction energy parameters of slab model, universal 
forcefield36 and mulliken charges37 obtained from DFT were employed. Atomic charges employed in 
MD simulation are summarized in Table S1. For HA polymers and water molecules, consistent-
valence forcefield (CVFF)38 was applied to describe bonding and non-bonding interaction parameters. 
Lorentz-Berthelot combination rule39, 40 was applied for the van der Waals parameters between slab 
model and HA or water in the system.
Density Functional Theory (DFT): We investigated the formation mechanism of coordination bond 
between HA and Zr6 metal node using DMol3 program.41, 42 The mechanism was predicted to be a 
dehydration condensation reaction by the interaction between the carboxylic acid functional group of 
HA and the hydroxyl group coordinated to the metal node. For the DFT calculation, we employed the 
Perdew-Burke-Ernzerhof (PBE) exchange-correlation functional43 and DNP 4.4 basis set with the all-
electron relativistic core treatment. The convergence criteria for energy, force, and displacement were 
set to 1×10-5 Ha, 0.002 Ha/Å, and 0.005 Å, respectively. To include the dispersion correction of the 
van der Waals effect, the Tkatchenko-Scheffler scheme was used.44 The electrostatic contribution in 
hydrated condition was considered by applying the Conductor-like Screening Model (COSMO) 
method45, with the dielectric constants of water (ε = 78.54). To calculate transition states in the 
formation mechanism of the coordination bond between Ha and Zr6 metal node, we employed 
complete single linear synchronous transit (LST) and quadratic synchronous transit (QST) methods46, 
47, and the convergence criteria of the root mean square (RMS) force was set as 0.002 Ha/Å
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Chapter 5. Polyvalent interaction between MOF and polymer for effective 
cancer therapy.
5.1 Abstract
NanoMOF, with a high surface, porous and easily adjustable structure, has attracted much attention 
in drug delivery systems. In particular, the unsaturated metal clusters present on the MOF surface can 
easily form coordination bonds with Lewis compounds for post-functionalization. Various nanoMOF 
drug delivery systems utilize this feature to modify cancer-targeting ligands or DNA on the MOF 
surface, but various proteins and bio chemical with Lewis bases are present in the body, and these 
substances induce the detachment of the modified ligand on the MOF surface. Therefore, in order to 
prevent the above detachment and to enhance its therapeutic effects in cancer treatment, we studied a 
stable system in the body by combining multivalent coordination of MOF with polymer.
5.2 Introduction
The metal organic framework (MOF), characterized by a simple manufacturing method, high 
surface area, porosity, and structure controllability, consists of an inorganic building block (metal ion 
or metal oxide cluster) and an organic linker.1 It is used in catalysis,2-4 gas storage,5-7 separation,8-10 or 
sensing11-13 industrial fields. 
Recently, nanosized MOF (nanoMOF) has been used as a carrier of drugs,14-16 nucleic acids,17
peptdies, and proteins18-19 in bio application and also as in photodynamic therapy20-21 and as a MRI 
contrast agent20-21 using its inherent characteristics. The surface of MOF was functionalized with 
various functional groups for more effective use, such as cancer-targeting ability and increase of body 
stability of nanoparticles.21-23 Several post-synthetic modification procedures, such as surface 
adsorption,24-25 lipid coating,26-27 and covalent conjugation,28-29 have been reported. However, these 
methods have various problems, such as weak interaction with MOF, additional chemical reaction for 
modification.19, 30 To solve this problem, coordination bonding between MOF and Lewis base are used 
for ligand modification. 
Cancer-targeting ligands, DNA, and peptides were modified using a coordination bond.21, 31-32
However, various proteins and biochemicals with Lewis base functional groups are endogenous,33 and 
may competitively interact with the functional groups attached to the surface of the MOF, which may 
cause ligand detachment from the MOF. This phenomenon limits the use of MOF but has not been 
studied extensively. 
In this paper, we investigate the interaction between PCN-224, which has high stability in aqueous 
solutions, and cancer-targeting ligands with Lewis base functional groups. Folic acid with carboxylic 
acid functional group and polyacrylic acid with modified folic acid (Folic-PAA) are modified on the 
MOF surface by forming monovalent and polyvalent coordination bond, respectively. To observe the 
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stability of nanoparticles, PCN-224 modified with Folic acid and Folic-PAA was incubated in a cell 
culture media containing fetal bovine serum albumin (FBS), and the detachment of folic acid was 
quantified by high performance liquid chromatography (HPLC). The monovalent binding of folic acid 
showed unstable ligand modification in the culture medium resulting in decreased cancer-targeting 
ability. Meanwhile, Folic-PAA with polyvalent bonding showed stable modification ability and high 
cancer-targeting ability.
5.3 Results and discussion
PCN-224 was synthesized according to a previously published paper.21 The synthesized 
nanoparticles were identified by TEM and SEM. The nanoparticles have 100 nm size and sphere 
morphology (Figure 5-1a, b). PCN-224 of this size has higher cellular uptake capability than PCN-
224 of other sizes. Folic acid and folic acid-modified polyacrylic acid were modified on the MOF 
surface by stirring with PCN-224 in the solution state. The carboxylic acid group of folic acid forms a 
monovalent coordination bond with MOF, and the remaining carboxylic acid group of PAA forms a 
polyvalent coordination bond with MOF. After modification of Folic acid and Folic-PAA ligand to 
the MOF, the hydrodynamic size changed from 106 nm to 140 nm when PAA-folic acid was modified 
and did not change significantly when folic acid was modified (Figure 5-1c). 
Figure 5-1. a) TEM and b) SEM image of PCN-224. c)DLS data and d) zeta potential of PCN-224, 
Folic-PCN, and Folic-PAA-PCN
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This that modification of the small molecule Folic acid does not affect the size of the nanoparticle, 
but relatively bulky PAA modification affects the hydrodynamic size of the nanoparticle. In contrast, 
the surface charge of nanoparticles modified with Folic acid and Folic-PAA changed from 31.8 mV to 
23.3 and -20.4, respectively (Figure 5-1d). The above results indicate that Folic acid and Folic-PAA 
were modified on MOF surface. 
To determine the amount of folic acid modified on the surface of MOF, the amount of folic acid 
was calculated by measuring the amount of folic acid in the supernatant obtained by modifying Folic 
acid in PCN-224. The supernatant was analyzed by HPLC and it was confirmed that about 11 μg of 
folic acid was modified on 137 μg of PCN-224.
In order to confirm the stability of Folic-PCN, it was incubated for 1, 2, and 4 hours in cell culture 
media containing 10% PBS. After media incubation, the hydrodynamic size of nanoparticles 
increased from 106 nm to 122 nm by about 15 nm (Figure 5-2a). Folic acid detached from MOF was 
analyzed by HPLC and folic acid was observed at about 7 min (Figure 5-2b). The amount of detached 
Folic acid from MOF were 2.5, 2.8, and 4.8 μg at 1, 2, and 4 hours, respectively, corresponding to 22, 
25, and 44% of the modified amounts (Table 5-1).
Figure 5-2. a) DLS data of PCN-224, Folic-PCN and media incubated Folic-PCN; b) HPLC 
chromatogram of Folic-PCN incubated media supernatant at different incubation time; c) DLS data of 
Folic-PCN after incubated different FBS concentration media; d) HPLC chromatogram of Folic-PCN 
incubated media supernatant at different FBS concentration
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Table 5-1. Calculated detached amount of folic acid from PCN-224 surface.
When the Folic-PCN was incubated in cell culture media with different FBS concentrations, the 
hydrodynamic size of the nanoparticles increased to 148 nm in 10% FBS and increased to 
approximately 220 nm in 20, 30, 40, and 50% FBS. The detachment of folic acid was analyzed by 
HPLC. The amount of detached folic acid was 5.2, 4.7, 4.4, 4.4 and 3.7 μg at 10, 20, 30, 40, and 50%, 
respectively, with an average of about 40% of folic acid detached from MOF (Table 5-1). The above 
results show that modified folic acid was detached by protein and biochemical present in the body, 
and the amount of detached folic acid is increased as the time of circulation in the body increases. 
To observe the cellular uptake ability of nanoparticles by the effect of Folic acid detachment, Nile 
red-loaded folic-PCN and Folic-PAA-PCN was incubated to cell culture media containing 10% PBS 
for 4 hours (Figure 5-3). After incubation, the nanoparticles were added to Hela cells and the cellular 
uptake ability was confirmed by confocal microscopy (Figure 5-3). Folic-PAA-PCN showed a higher 
red fluorescence than Folic-PCN even without media incubation. After incubation, the fluorescence of 
Folic-PCN was decreased while the fluorescence of folic-PAA-PCN was still strong. The results show 
that folic-PAA-PCN penetrates cancer cells more effectively than folic-PCN and folic acid is losing 
the cellular uptake ability by biomaterials, while folic-PAA-PCN is not significantly affected.
Figure 5-3. Confocal microscopy image of Folic-PCN and Folic-PAA-PCN (nanoparticles were 
incubated in media for 4 h)
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5.4 Summary
In summary, folic acid is easily modified through monovalent coordination bonds with PCN-224. 
However, various proteins and biochemicals containing a Lewis base in the body competitively 
interact with MOF to induce the detachment of folic acid, decreasing the cellular uptake ability of 
Folic-PCN. In order to prevent this, folic-PAA, which can be stably modified through polyvalent 
coordination, was modified on the surface of PCN-224. Unlike folic-PCN, Folic-PAA-PCN showed 
high cell uptake ability after cell culture media incubation. These results suggest that modifying the 
ligand through polyvalent interaction with MOF can be used more effectively as a drug delivery 
system.
5.5 Experimental
Figure 5-4. HPLC calibration curve of folic acid
General information: All chemicals and reagents were purchased from Sigma-Aldrich, TCI and Alfa 
Aesar, Korea unless otherwise specified and used without further purifications. Doxorubicin 
hydrochloride was obtained from Ontario Chemicals Inc, Canada. Deionized (DI) water was produced 
by the Millipore Milli-Q system (18.2 MΩ cm).
Preparation of PCN-224 (90 nm): PCN-224 nanoparticles were synthesized in a solvothermal 
condition as reported.30 Meso-Tetra(4-carboxyphenyl)porphine (TCPP) (100mg, 0.13mmol), 
ZrOCl2·8H2O (300mg, 0.93mmol), benzoic acid (2.8g, 23mmol) and DMF (100mL) were combined 
in a 250mL round-bottom flask. The mixture was heated to 90 °C for 5hours with 300rpm stirring and 
then cooled to room temperature. The product was collected by centrifugation with 15000rpm for 
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30min and washed by fresh DMF and acetone. The synthesized PCN-224 sample was characterized 
by powder X-ray diffraction (PXRD).
Preparation of Nlie red-PCN: About 4 mg of PCN-224 were dispersed in 1mg of Nile red were 
dissolved in 1 mL of DMSO and stir for 24 hours at room temperature. Then the Nile red loaded 
PCN-224 was collected by centrifugation and dried under high vacuum. Then dried samples were 
redispersed in DI water.
Preparation of Folic-PAA: To a stirred solution of 2,2-(ethylenedioxy)-bis- (ethylamine) (1.48 g, 10 
mmol) in 10 ml anhydrous CHCl3, BoC2O (0.218 g, 1 mmol) in 5 ml CHCl3 was added dropwise at 0 
◦C under argon atmosphere. The reaction mixture was warmed to room temperature and stirred for 24 
h. Then the solvent was removed under reduced pressure and the thick oil so obtained was diluted 
with CH2Cl2. The organic layer was washed with brine, dried over anhydrous NaSO, and concentrated 
under reduced pressure.  To a stirred solution of folic acid (330 mg, 0.75 mmol) in 20 ml anhydrous 
DMSO and pyridine (8 ml), was added synthesized chemical (216 mg, 0.87 mmol) and dicyclohexyl 
carbodiimide (410 mg, 2 mmol) at room temperature under argon atmosphere. The reaction mixture 
was stirred for 18 h at room temperature and the resulting precipitate was filtered. The filtrate was 
gradually poured into a vigorously stirred Et2O (50 ml) at 0 
◦C. The yellow precipitate thus obtained 
was collected and washed with cold Et2O several times to remove trace of DMSO. Then the solvent 
was removed under reduced pressure to give 2 (450 mg, 90%) as a yellow solid.
Preparation of Folic-PCN, Folic-PAA-PCN: About 1.38 mg of PCN were dispersed in 0.95 mL of 
DI water and add the 50 μl folic acid or Folic-PAA solution (2.21 mg/ml in DMSO)) and stir for 24 
hours at room temperature. Then folic acid modified PCN-224 was collected by centrifugation and 
redispersed in DI water. The supernatant solution containing unmodified Folic acid were analyzed by 
HPLC.
Cellular uptake analysis: The cellular uptake of Folic-PCN and Folic-PAA-PCN nanoparticles in  
hela cells were investigated by live confocal microscope images (Olympus FV 1000 series). The cells 
were seeded at a density of 2 x 105 cells/well in two well chambered cover glass (Lab Tek II, Thermo 
Scientific. After 24 hours incubation, cells were treated with Folic-PCN or Folic-PAA-PCN at a final 
concentration of 10 µg/mL at different time points and analyzed using the confocal microscope.
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